1
|
Zhou Y, Zhou Y, Xu D, Min J, Du Y, Duan Q, Bao W, Sun Y, Xi H, Wang C, Bischof E. Practice Standards in International Medical Departments of Public Academic Hospitals in China: Cross-Sectional Study. JMIR Form Res 2024; 8:e53898. [PMID: 38739428 DOI: 10.2196/53898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 03/07/2024] [Accepted: 03/14/2024] [Indexed: 05/14/2024] Open
Abstract
BACKGROUND Improving health care in cities with a diverse, international population is crucial for ensuring health equity, particularly for foreigners facing challenges due to cultural and language barriers. This situation is especially relevant in China, a major destination for expatriates and travelers, where optimizing health care services and incorporating international standards in the public sector are vital. Achieving this involves understanding the operational details, cultural and linguistic nuances, and advancing medical digitalization. A strategic approach focusing on cultural competence and awareness of health care systems is essential for effectively navigating health care for foreigners and expatriates in China. OBJECTIVE The aim of this study was to perform an in-depth analysis of the subjective and objective experiences of local and international patients in public hospitals in China to provide a basis for enhancing the medical experience of all patients. METHODS A structured questionnaire was provided to patients at an international outpatient service of a top-tier university hospital in China. Qualitative analysis of the survey responses was performed to methodically categorize and analyze medical treatment, focusing on patient demand and satisfaction across four main category elements ("high demand, high satisfaction"; "high demand, low satisfaction"; "low demand, high satisfaction"; and "low demand, low satisfaction"), enabling a detailed cross-sectional analysis to identify areas for improvement. RESULTS Elements falling under "high demand, high satisfaction" for both Chinese and international patients were primarily in the realms of medical quality and treatment processes. In contrast, elements identified as "high demand, low satisfaction" were significantly different between the two patient groups. CONCLUSIONS The findings highlight the importance of systematic, objective research in advancing the quality of international health care services within China's leading academic medical centers. Key to this improvement is rigorous quality control involving both patients and providers. This study highlights the necessity of certifying such centers and emphasizes the role of digital platforms in disseminating information about medical services. This strategy is expected to cater to diverse patient needs, enhancing the overall patient experience. Furthermore, by developing comprehensive diagnosis and treatment services and highlighting the superior quality and costs associated with international health care, these efforts aim to foster a sense of belonging among international patients and increase the attractiveness of China's medical services for this demographic.
Collapse
Affiliation(s)
- Yaxu Zhou
- Finance Department, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Ying Zhou
- Smart Hospital Development Department, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Di Xu
- International Medical Service, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Jie Min
- International Medical Service, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Yu Du
- International Medical Service, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Qi Duan
- International Medical Service, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Wen Bao
- International Medical Service, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Yingying Sun
- International Medical Service, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Huiqin Xi
- Nursing Department, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Chunming Wang
- Smart Hospital Development Department, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Evelyne Bischof
- Department of Oncology and Clinical Cancer Center, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, China
- Department of Oncology, Reni Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
| |
Collapse
|
2
|
Wang M, Qin L, Bao W, Xu Z, Han L, Yan F, Yang W. Epicardial and pericoronary adipose tissue and coronary plaque burden in patients with Cushing's syndrome: a propensity score-matched study. J Endocrinol Invest 2024:10.1007/s40618-023-02295-x. [PMID: 38308163 DOI: 10.1007/s40618-023-02295-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Accepted: 12/28/2023] [Indexed: 02/04/2024]
Abstract
PURPOSE To assess coronary inflammation by measuring the volume and density of the epicardial adipose tissue (EAT), perivascular fat attenuation index (FAI) and coronary plaque burden in patients with Cushing's syndrome (CS) based on coronary computed tomography angiography (CCTA). METHODS This study included 29 patients with CS and 58 matched patients without CS who underwent CCTA. The EAT volume, EAT density, FAI and coronary plaque burden were measured. The high-risk plaque (HRP) was also evaluated. CS duration from diagnosis, 24-h urinary free cortisol (UFC), and abdominal visceral adipose tissue volume (VAT) of CS patients were recorded. RESULTS The CS group had higher EAT volume (146.9 [115.4, 184.2] vs. 119.6 [69.0, 147.1] mL, P = 0.006), lower EAT density (- 78.79 ± 5.89 vs. - 75.98 ± 6.03 HU, P = 0.042), lower FAI (- 84.0 ± 8.92 vs. - 79.40 ± 10.04 HU, P = 0.038), higher total plaque volume (88.81 [36.26, 522.5] vs. 44.45 [0, 198.16] mL, P = 0.010) and more HRP plaques (7.3% vs. 1.8%, P = 0.026) than the controls. The multivariate analysis suggested that CS itself (β [95% CI], 29.233 [10.436, 48.03], P = 0.014), CS duration (β [95% CI], 0.176 [0.185, 4.242], P = 0.033), and UFC (β [95% CI], 0.197 [1.803, 19.719], P = 0.019) were strongly associated with EAT volume but not EAT density, and EAT volume (β [95% CI] - 0.037[- 0.058, - 0.016], P = 0.001) not CS was strongly associated with EAT density. EAT volume, FAI and plaque burden increased (all P < 0.05) in 6 CS patients with follow-up CCTA. The EAT volume had a moderate correlation with abdominal VAT volume (r = 0.526, P = 0.008) in CS patients. CONCLUSIONS Patients with CS have higher EAT volume and coronary plaque burden but less inflammation as detected by EAT density and FAI. The EAT density is associated with EAT volume but not CS itself.
Collapse
Affiliation(s)
- M Wang
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Er Road, Shanghai, 200025, China
| | - L Qin
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Er Road, Shanghai, 200025, China
| | - W Bao
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Er Road, Shanghai, 200025, China
| | - Z Xu
- Siemens Healthineers CT Collaboration, Shanghai, China
| | - L Han
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Er Road, Shanghai, 200025, China
| | - F Yan
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Er Road, Shanghai, 200025, China
| | - W Yang
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Er Road, Shanghai, 200025, China.
| |
Collapse
|
3
|
Zhang S, Wu Y, Bao W. Exploring the motivations for rural tourism in China during the COVID-19: The existence of a single motivation. PLoS One 2023; 18:e0294610. [PMID: 38055676 PMCID: PMC10699599 DOI: 10.1371/journal.pone.0294610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 11/05/2023] [Indexed: 12/08/2023] Open
Abstract
The COVID-19 epidemic had an appropriate impact on tourists' trip psychology and their subsequent behavior in participating in rural tourism activities. The purpose of this paper is to explore the types of motivations Chinese tourists have for participating in rural tourism in the context of COVID-19, and to comparatively analyze the similarities and differences in motivations for rural tourism during the epidemic and in normal times. An interpretive paradigm qualitative data collection method was used: semi-structured interviews and focus group discussions. Respondents were 21 tourists, who were selected through purposive and snowball sampling. Through content analysis, we found that rural tourism motivations during the epidemic included both diversified and singular motivations. The pull effect of rural destinations is related to distance and ease of realization. For rural areas in close proximity, a single motivation is sufficient to drive tourists. In addition, we found that there was no "altruistic motivation" for rural tourism during the COVID-19 period, but "altruistic feelings" for the preservation of ancient villages were generated during rural tourism. Finally, we discuss the theoretical and practical significance of this study and make suggestions for future research. The study explains tourists' companionship preferences, activity choices, and affective changes, and provides a basis for the operation and advertising strategies of rural destinations to attract tourists and promote their sustainable development.
Collapse
Affiliation(s)
- Songting Zhang
- School of History, Culture and Tourism, Fuyang Normal University, Fuyang, Anhui Province, China
| | - Yichao Wu
- Yuexiu Institute of Hospitality Administration, Zhejiang Yuexiu University, Shaoxing, Zhejiang Province, China
| | - Wen Bao
- Department of Tourism, Lanzhou Vocational and Technical College, Lanzhou, Gansu Province, China
| |
Collapse
|
4
|
Zheng TL, Huo CY, Bao W, Xu XT, Dai WH, Cheng F, Duan DS, Yang LL, Zhang XM, Zhu DY, Wang SH. Au-Catalyzed Asymmetric Polyene Cyclization and Its Application in the Total Synthesis of (+)-2-Ketoferruginol, (+)-Fleuryinol B, (+)-Salviol, and (-)-Erythroxylisin A. Org Lett 2023; 25:7476-7480. [PMID: 37811851 DOI: 10.1021/acs.orglett.3c02417] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/10/2023]
Abstract
A catalytic asymmetric 1,3-acyloxy shift/polyene cyclization cascade has been achieved with good enantioselectivities under the catalysis of the chiral Au(I) reagent. The synthetic utility of this method has been showcased by the catalytic asymmetric total syntheses of (+)-2-ketoferruginol, (+)-fleuryinol B, and (+)-salviol. Notably, the first enantioselective total synthesis of (-)-erythroxylisin A has also been realized in 15 steps.
Collapse
Affiliation(s)
- Tian-Lu Zheng
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000,P. R. China
| | - Chen-Yu Huo
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000,P. R. China
| | - Wen Bao
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000,P. R. China
| | - Xue-Tao Xu
- School of Biotechnology and Health Science, Wuyi University, Jiangmen 529020,P. R. China
| | - Wei-Hao Dai
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000,P. R. China
| | - Fu Cheng
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000,P. R. China
| | - Dong-Sen Duan
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000,P. R. China
| | - Le-Le Yang
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000,P. R. China
| | - Xiao-Ming Zhang
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000,P. R. China
| | - Dao-Yong Zhu
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000,P. R. China
| | - Shao-Hua Wang
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000,P. R. China
- School of Biotechnology and Health Science, Wuyi University, Jiangmen 529020,P. R. China
| |
Collapse
|
5
|
Bao W, Liu R, Wang F, Nie C, Qian LB, Chen L, Wang Y, Chen BA. [Basic Research on Therapy of Leukemia with Nanoparticles Drug Delivery System Modified by Transferrin Receptor Monoclonal Antibody]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2023; 31:939-944. [PMID: 37551459 DOI: 10.19746/j.cnki.issn.1009-2137.2023.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 08/09/2023]
Abstract
OBJECTIVE To investigate the therapeutic effect of targeted drug-loaded nanoparticles modified by transferrin receptor monoclonal antibody (TfR mAb) on acute leukemia and its potential anti-tumor mechanism. METHODS Nanoparticles drug delivery system, which was composed of poly (lactic-co-glycolic acid), poly-l-lysine, polyethylene glycol, TfR mAb (TfR mAb-PLGA-PLL-PEG)-daunorubicin (DNR), was first synthesized. After drug intervention, the intracellular accumulation in leukemia HL60 cells was observed under a fluorescent microscope and concentration of DNR was determined by flow cytometry (FCM). Meanwhile, cell apoptosis rate was measured by FCM and the expression levels of apoptosis related protein Cleaved-caspase 3 was determined by Western blot. RESULTS Under an inverted fluorescent microscope, intracellular accumulation of DNR autofluorescence in HL60 cells was observed in both TfR mAb-PLGA-PLL-PEG-DNR group and DNR group. FCM analysis showed that the intracellular concentration of DNR in TfR mAb-PLGA-PLL-PEG-DNR group was higher than that in DNR group(P<0.05). The apoptotic rate of HL60 cells in TfR mAb-PLGA-PLL-PEG-DNR group was higher than that of DNR group(P<0.05). Moreover, the expression levels of apoptosis-related protein Cleaved-caspase 3 in TfR mAb-PLGA-PLL-PEG-DNR group was significantly higher than that in DNR group(P<0.05). CONCLUSION TfR mAb-PLGA-PLL-PEG nanoparticle drug delivery system can target chemotherapy drugs to leukemia cells and enhance anticancer ability through apoptotic pathway.
Collapse
Affiliation(s)
- Wen Bao
- Jiangsu Health Vocational College, Nangjing 211800, Jiangsu Province, China
| | - Ran Liu
- Department of Hematology, Zhongda Hospital, Southeast University Medical College, Nangjing 210009, Jiangsu Province, China
| | - Fei Wang
- Department of Hematology, Zhongda Hospital, Southeast University Medical College, Nangjing 210009, Jiangsu Province, China
| | - Chao Nie
- Jiangsu Health Vocational College, Nangjing 211800, Jiangsu Province, China
| | - Li-Bing Qian
- Jiangsu Health Vocational College, Nangjing 211800, Jiangsu Province, China
| | - Ling Chen
- Jiangsu Health Vocational College, Nangjing 211800, Jiangsu Province, China
| | - Yan Wang
- Jiangsu Health Vocational College, Nangjing 211800, Jiangsu Province, China
| | - Bao-An Chen
- Department of Hematology, Zhongda Hospital, Southeast University Medical College, Nangjing 210009, Jiangsu Province, China,E-mail:
| |
Collapse
|
6
|
Deng C, Li S, Liu Y, Bao W, Xu C, Zheng W, Wang M, Ma X. Split-Cas9-based targeted gene editing and nanobody-mediated proteolysis-targeting chimeras optogenetically coordinated regulation of Survivin to control the fate of cancer cells. Clin Transl Med 2023; 13:e1382. [PMID: 37620295 PMCID: PMC10449816 DOI: 10.1002/ctm2.1382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2023] [Revised: 08/09/2023] [Accepted: 08/12/2023] [Indexed: 08/26/2023] Open
Abstract
BACKGROUND Precise regulation of partial critical proteins in cancer cells, such as anti-apoptotic proteins, is one of the crucial strategies for treating cancer and discovering related molecular mechanisms. Still, it is also challenging in actual research and practice. The widely used CRISPR/Cas9-based gene editing technology and proteolysis-targeting chimeras (PROTACs) have played an essential role in regulating gene expression and protein function in cells. However, the accuracy and controllability of their targeting remain necessary. METHODS Construction of UMUC-3-EGFP stable transgenic cell lines using the Sleeping Beauty system, Flow cytometry, quantitative real-time PCR, western blot, fluorescence microplate reader and fluorescence inverted microscope analysis of EGFP intensity. Characterization of Survivin inhibition was done by using Annexin V-FITC/PI apoptosis, calcein/PI/DAPI cell viability/cytotoxicity assay, cloning formation assay and scratch assay. The cell-derived xenograft (CDX) model was constructed to assess the in vivo effects of reducing Survivin expression. RESULTS Herein, we established a synergistic control platform that coordinated photoactivatable split-Cas9 targeted gene editing and light-induced protein degradation, on which the Survivin gene in the nucleus was controllably edited by blue light irradiation (named paCas9-Survivin) and simultaneously the Survivin protein in the cytoplasm was degraded precisely by a nanobody-mediated target (named paProtacL-Survivin). Meanwhile, in vitro experiments demonstrated that reducing Survivin expression could effectively promote apoptosis and decrease the proliferation and migration of bladder cancerous cells. Furthermore, the CDX model was constructed using UMUC-3 cell lines, results from animal studies indicated that both the paCas9-Survivin system and paProtacL-Survivin significantly inhibited tumour growth, with higher inhibition rates when combined. CONCLUSIONS In short, the coordinated regulatory strategies and combinable technology platforms offer clear advantages in controllability and targeting, as well as an excellent reference value and universal applicability in controlling the fate of cancer cells through multi-level regulation of key intracellular factors.
Collapse
Affiliation(s)
- Changping Deng
- State Key Laboratory of Bioreactor EngineeringEast China University of Science and TechnologyShanghaiP. R. China
| | - Shihui Li
- State Key Laboratory of Bioreactor EngineeringEast China University of Science and TechnologyShanghaiP. R. China
| | - Yuping Liu
- Shanghai Key Laboratory of New Drug DesignSchool of PharmacyEast China University of Science and TechnologyShanghaiP. R. China
| | - Wen Bao
- Shanghai Key Laboratory of New Drug DesignSchool of PharmacyEast China University of Science and TechnologyShanghaiP. R. China
| | - Chengnan Xu
- Shanghai Key Laboratory of New Drug DesignSchool of PharmacyEast China University of Science and TechnologyShanghaiP. R. China
| | - Wenyun Zheng
- Shanghai Key Laboratory of New Drug DesignSchool of PharmacyEast China University of Science and TechnologyShanghaiP. R. China
| | - Meiyan Wang
- Synthetic Biology and Biomedical Engineering LaboratoryBiomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory BiologyInstitute of BiomedicalSciences and School of Life SciencesEast China Normal UniversityShanghaiP. R. China
| | - Xingyuan Ma
- State Key Laboratory of Bioreactor EngineeringEast China University of Science and TechnologyShanghaiP. R. China
| |
Collapse
|
7
|
Zhang BH, Bao W, Cheng F, Yu KY, Wang JX, Zhang ZH, Dong LJ, Xue ZS, Zhu DY, Xu XT, Wang SH. Rh(I)-Catalyzed [5 + 2]/[2 + 2] Cycloaddition Cascade to Access a Cyclobutane-Fused [4-5-6-7] Tetracyclic Framework. Org Lett 2023; 25:2405-2409. [PMID: 37014308 DOI: 10.1021/acs.orglett.3c00466] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]
Abstract
A Rh(I)-catalyzed [5 + 2]/[2 + 2] cycloaddition cascade has been developed to afford a complex and highly strained [4-5-6-7] tetracyclic framework in good yields and excellent diastereoselectivities. During this transformation, three rings, three C-C bonds, and four contiguous stereocenters were formed efficiently. Mechanistically, the rare sterically congested multisubstituted cyclobutanes are constructed readily through Michael addition and a Mannich reaction cascade.
Collapse
Affiliation(s)
- Bang-Hong Zhang
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China
| | - Wen Bao
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China
| | - Fu Cheng
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China
| | - Ke-Yang Yu
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China
| | - Jia-Xuan Wang
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China
| | - Zi-Hao Zhang
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China
| | - Long-Jun Dong
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China
| | - Ze-Sen Xue
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China
| | - Dao-Yong Zhu
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China
| | - Xue-Tao Xu
- School of Biotechnology and Health Science, Wuyi University, Jiangmen 529020, China
| | - Shao-Hua Wang
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China
| |
Collapse
|
8
|
Han W, Kong R, Wang N, Bao W, Mao X, Lu J. Confocal Laser Endomicroscopy for Detection of Early Upper Gastrointestinal Cancer. Cancers (Basel) 2023; 15:cancers15030776. [PMID: 36765734 PMCID: PMC9913498 DOI: 10.3390/cancers15030776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Revised: 01/19/2023] [Accepted: 01/23/2023] [Indexed: 01/28/2023] Open
Abstract
Esophageal and gastric cancers are common diseases with high morbidity and mortality; thus, early detection and treatment are beneficial to improve prognosis. Confocal laser endomicroscopy (CLE) is a novel imaging technique that permits the histological analysis of tissues during endoscopy. CLE has been shown to uniquely affect the diagnosis of early upper gastrointestinal cancers. Relevant literature was searched using PubMed and Google Scholar databases. Despite inherent flaws, CLE can reduce tissue damage and improve diagnostic accuracy to a certain extent. CLE in combination with other imaging methods can help enhance the detection rate and avoid unnecessary biopsies in the management of esophageal or gastric cancer and precancerous lesions. CLE is of great significance in the diagnosis and surveillance of early cancers of the upper gastrointestinal tract. Further technical innovations and the standardisation of CLE will make it more responsive to the needs of routine clinical applications.
Collapse
Affiliation(s)
- Wei Han
- Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
| | - Rui Kong
- Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
| | - Nan Wang
- Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
| | - Wen Bao
- Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
| | - Xinli Mao
- Department of Gastroenterology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Zhejiang 317099, China
- Correspondence: (X.M.); (J.L.)
| | - Jie Lu
- Department of Gastroenterology, Gongli Hospital of Shanghai Pudong New Area, Shanghai 200135, China
- Correspondence: (X.M.); (J.L.)
| |
Collapse
|
9
|
Jin DP, Cao SQ, Cheng F, Xue ZS, Li RZ, Pu YL, Zhu DY, Bao W, Xu XT, Wang SH. A Gold(I)‐Catalyzed Cyclization/Semipinacol Rearrangement Cascade of 1,6‐Enynes to Access Spiro[4.5]decanes and 7‐Azaspiro[4.5]decanes. Adv Synth Catal 2023. [DOI: 10.1002/adsc.202201266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- Da-Ping Jin
- State Key Laboratory of Applied Organic Chemistry CHINA
| | | | | | | | | | | | | | | | | | - Shao-Hua Wang
- State Key Laboratory of Applied Organic Chemistry CHINA
| |
Collapse
|
10
|
Bao W, Wu D, Han W, Kong R, Wang N, Lu J. Efficacy of Different Pancreatic Interventional Treatments for Chronic Calcific Pancreatitis: A Two-Year Multicenter Retrospective Study. Int J Gen Med 2022; 15:7511-7521. [PMID: 36187161 PMCID: PMC9522486 DOI: 10.2147/ijgm.s383780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Accepted: 09/07/2022] [Indexed: 11/23/2022] Open
Abstract
Background Extracorporeal shock wave lithotripsy (ESWL) and endoscopic retrograde cholangiopancreatography (ERCP) are the main treatments for chronic calcific pancreatitis (CCP). However, clinical outcomes remain unclear for patients underwent different interventional therapies based on these two techniques. Methods A total of 125 patients with CCP who underwent ESWL, ERCP or a combined treatment at two medical centers from January 2019 to January 2020 were considered. Patients were divided into four groups according to intervention types (ESWL-alone, ERCP-alone, ESWL-ERCP and ERCP-ESWL). A retrospective survey with a follow-up for 2 years was conducted. The main outcome measures were postoperative complications, abdominal pain and re-intervention during the follow-up. Possible prognostic factors were evaluated by multivariate analysis. Results Patients in ESWL-ERCP group had the highest complete pain relief rate (49.28%), the lowest pain frequency (1 time/year) and intensity (VAS-score, 1.84±1.93) during the follow-up, which were statistically significant compared with the other three groups. ESWL-ERCP group also had the lowest postoperative complication rate (6%), while the highest complication rate (16%) was observed in ESWL-alone group. Both ESWL-alone and ESWL-ERCP group had significant lower frequencies of re-interventions (0.44 ± 0.73, 0.57±0.98, respectively) after the initial treatments. An analysis of treatment-based prognostic factors found significant interactions between age, course of CCP, max pancreatic duct stone diameter, calcium, glycosylated hemoglobin (HbA1c) and triglyceride. Conclusion ESWL-ERCP was considered as the most effective interventional therapy for CCP with a better safety in a two-year follow-up. Prognostic factors may help to determine the patients who benefit by this technique.
Collapse
Affiliation(s)
- Wen Bao
- Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, 200072, People’s Republic of China
| | - Deqing Wu
- Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, 200072, People’s Republic of China
| | - Wei Han
- Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, 200072, People’s Republic of China
| | - Rui Kong
- Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, 200072, People’s Republic of China
| | - Nan Wang
- Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, 200072, People’s Republic of China
| | - Jie Lu
- Department of Gastroenterology, Gongli Hospital, School of Medicine, Shanghai University, Shanghai, 200135, People’s Republic of China
- Correspondence: Jie Lu, Email
| |
Collapse
|
11
|
D’Agostino MA, Boers M, Gaillez C, Gamez C, Ventura L, Rosa J, Padovano I, Mandl P, Kleyer A, Bakewell C, Bao W, Goyanka P, Conaghan PG, Schett G. OP0260 RESPONSIVENESS OF A COMBINED POWER DOPPLER AND GREYSCALE ULTRASOUND SCORE FOR ASSESSING SYNOVITIS AT JOINT LEVEL IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO csDMARDs: DATA FROM THE ULTIMATE TRIAL. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundPower Doppler ultrasound (PDUS) is a sensitive non-invasive imaging tool that allows the visualisation of articular and periarticular inflammation in patients with psoriatic arthritis (PsA).1 ULTIMATE (NCT02662985) was the first large randomised clinical trial that showed the responsiveness of the Global OMERACT-EULAR ultrasound synovitis score (GLOESS) in PsA and confirmed the rapid and continued benefits of secukinumab through 52 weeks.2,3ObjectivesTo report the distribution of ultrasound-detected synovitis at joint level, by degree of severity at baseline and over time, and the contribution of each core component of GLOESS, synovial hypertrophy (SH) by greyscale (GS; B-mode) and power Doppler (PD) signal, to responsiveness.3MethodsThis was a 52-week study with a 12-week double-blind, placebo-controlled treatment period followed by a 12-week open-label period and a 6-month open-label extension secukinumab treatment period.3 The number of joints with synovitis measured by GLOESS2 was assessed up to Week 52. The assessments included distribution of synovitis based on composite PDUS score across 24 pairs of joints (with worse score of the pair of the joints used) by grade of severity (0-3) and change from baseline to Week 52 in each core component of GLOESS.3-5 Data are presented as observed.ResultsA total of 166 patients (mean age, 46.7 years; males, 45.2%) were enrolled, of which 90% (75/83) of secukinumab and 83% (69/83) of placebo-secukinumab participants completed 52 weeks. The mean (SD) number of PDUS detected synovitis at baseline was 9.2 (4.9) and 10.2 (5.2) in the secukinumab and placebo group, respectively. The most frequent locations with synovitis at baseline were: wrist, metatarsophalangeal (MTP), knees and metacarpophalangeal (MCP) joints (Table 1). An early and continued improvement in GLOESS was observed in both secukinumab and placebo-secukinumab groups after switching to active therapy, as previously reported at Week 12 and through Week 52.2,3 Among the two core components of GLOESS, SH was mainly responsible for the change in GLOESS from baseline to Week 52, in contrast with PD signal in this dataset. The distribution of synovitis by grade of severity showed that MTP joints, wrist, knee, MCP1/2 and tibiotalar joints mostly contributed to the composite PDUS at Week 12 (Figure 1). Similar patterns were observed through 52 weeks.Table 1.Proportion of patients with PDUS detected synovitis at baseline*Synovitis joint, data presented as n (%)Secukinumab (N=83)Placebo (N=83)Wrist66 (80)66 (80)MTP256 (68)65 (78)MTP158 (70)60 (72)MTP352 (63)60 (72)MTP446 (55)59 (71)Knee50 (60)47 (57.)MCP136 (43)52 (63)MCP235 (42)41 (49)MTP530 (36)41 (49)*Data for top nine pairs of joints with most frequently detected power Doppler ultrasound (PDUS) synovitis are presented here. Synovitis was scored by a OMERACT-EULAR synovitis composite score >0 for each paired joint (irrespective of right or left side). The OMERACT-EULAR composite PDUS score (for individual joints) ranged from 0 to 3 and was composed of the two core components synovial hypertrophy and power Doppler.N, total number of randomised patients; n, number of evaluable patientsConclusionThe distribution of synovitis at baseline reflected a predominance of small joints (feet and hands) and large joints (wrist and knee) and were mostly responsive to secukinumab over time in the ULTIMATE trial. Synovial hypertrophy was the most responsive core component of GLOESS driving an early and continued reduction of synovitis with secukinumab through Week 52. This finding could be useful to select a restricted number of joints in future ultrasound trials in PsA.References[1]D’Agostino MA and Coates LC. J Rheumatol. 2019;46:337–9.[2]D’Agostino MA et al. Arthritis Rheumatol. 2021;73(10).[3]D’Agostino MA, et al. Rheumatology (Oxford) 2021;keab628.[4]D’Agostino MA and Coates LC. RMD Open 2017;3:e000428.[5]Uson J, et al. Rheumatol Clin. 2018;14:27–35.Disclosure of InterestsMaria-Antonietta D’Agostino Speakers bureau: Sanofi, Novartis, BMS, Janssen, Celgene, Roche, AbbVie, UCB, and Eli Lilly, Consultant of: Sanofi, Novartis, BMS, Janssen, Celgene, Roche, AbbVie, UCB, and Eli Lilly, Maarten Boers Consultant of: Novartis, Corine Gaillez Shareholder of: Novartis and BMS, Employee of: Novartis, Carlos Gamez: None declared, LUCIO VENTURA: None declared, Javier Rosa Speakers bureau: Abbvie, Pfizer, Lilly, Janssen, Novartis and BMS, Ilaria Padovano: None declared, Peter Mandl Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Roche and UCB, Grant/research support from: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Roche and UCB, Arnd Kleyer Speakers bureau: Abbvie, Lilly, Novartis, MEDAC; Janssen, Consultant of: Abbvie, Lilly, UCB, Novartis, BMS, Sanofi, Galapagos, Catherine Bakewell Speakers bureau: AbbVie, Novartis, Pfizer, Janssen, UCB, and Sanofi Genzyme/Regeneron, Consultant of: AbbVie, Novartis, Pfizer, Janssen, UCB, and Sanofi Genzyme/Regeneron, Weibin Bao Shareholder of: Novartis, Employee of: Novartis, Punit Goyanka Employee of: Novartis, Philip G Conaghan Speakers bureau: AbbVie, Amgen, AstraZeneca, Eli Lilly, Galapagos, Gilead, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, AstraZeneca, Eli Lilly, Galapagos, Gilead, Novartis, Pfizer and UCB, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Roche and UCB
Collapse
|
12
|
D’Agostino MA, Boers M, Schett G, Conaghan PG, Naredo E, Mandl P, Carron P, Backhaus M, López-Rodríguez A, Hanova P, Goyanka P, Sahoo BG, Gaillez C, Bao W. OP0294 REDUCED JOINT SYNOVITIS ASSESSMENT VERSUS THE GLOBAL EULAR OMERACT SYNOVITIS SCORE (GLOESS) TO PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: EXPLORATORY RESULTS FROM THE ULTIMATE TRIAL. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThe combined use of B-mode ultrasound (US) and Power Doppler (PD; combination termed as PDUS) allows visualisation of morphological and pathophysiological changes of the synovium. ULTIMATE (NCT02662985) was the first large, randomised, double-blind, placebo-controlled PDUS phase IIIb study in psoriatic arthritis (PsA), to demonstrate that Global OMERACT EULAR Synovitis Score (GLOESS), a US score at patient level, was sensitive to detect the early and continuous decrease in synovitis in a multicenter setting using different US devices and examiners.1 However, the US assessment for GLOESS was time-consuming owing to the number of joints assessed.ObjectivesTo investigate the value of various reduced joint sets to predict the validated GLOESS score.MethodsULTIMATE was a 52-week study with a 12-week double-blind, placebo-controlled period followed by 12-week open-label (OL) treatment and 6-month OL extension period.1 In the ULTIMATE trial, GLOESS for the 24 paired joints was calculated, with a potential score ranging between 0 to 144.1 A Spearman’s rank correlation matrix and a Cluster Image Map were constructed to identify highly correlated joint clusters based on the composite PDUS scores. Based on the different approaches (best correlation, model optimization, etc.), representative joints were then selected from each group, which yielded several corresponding combinations of joints. Linear models were developed with these reduced joint sets as predictors of GLOESS, using data from 60% of patients randomly selected from the ULTIMATE study. The remaining 40% data were used for model validation and diagnostics.ResultsFive models were established with reduced pairs of joint sets (9–13 pairs). The joints included in each linear model are summarized in Table 1. All five models of reduced joint sets showed high correlation with GLOESS score of R2 ~ 0.95. Figure 1 depicts all the 5 models of reduced joint sets for PDUS-detected synovitis versus the actual GLOESS in secukinumab and placebo-secukinumab groups, with modified GLOESS scores using reduced PDUS joint sets demonstrating changes very close to that of validated GLOESS.Table 1.Joints included across five linear models, indicated by green shadingJoint pairsModel 1 (N=9)Model 2 (N=9)Model 3 (N=9)Model 4 (N=13)Model 5 (N=12)ElbowKneeMTP2WristMCP1DIP4MTP4MCP2MCP4MCP5PIP3PIP4PIP1, PIP5DIP2DIP3, DIP5MTP1MTP5ShoulderTibiotalarN, number of joint pairs used in model. DIP, distal interphalangeal; MCP, metacarpophalangeal; MTP, metatarsophalangeal;PIP, proximal interphalangealFigure 1.Reduced set of joints synovitis score vs GLOESS scoreConclusionAll models of reduced joint sets for PDUS-detected synovitis predicted GLOESS well. The next steps will be to document responsiveness and ability to discriminate between active and placebo treatment.References[1]D’Agostino MA, et al. Rheumatology (Oxford) 2021;keab628.Disclosure of InterestsMaria-Antonietta D’Agostino Speakers bureau: AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Roche, Sanofi, and UCB, Consultant of: AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Roche, Sanofi, and UCB, Maarten Boers Consultant of: BMS, GSK, Novartis, Pfizer, Consultant of: BMS, GSK, Novartis and Pfizer, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Roche and UCB, Philip G Conaghan Speakers bureau: AbbVie, AstraZeneca, BMS, Eli Lilly, Galapagos, Gilead, Novartis and Pfizer, Consultant of: AbbVie, AstraZeneca, BMS, Eli Lilly, Galapagos, Gilead, Novartis and Pfizer, Esperanza Naredo Speakers bureau: AbbVie, BMS, Celgene GmbH, Janssen, Lilly, Novartis, Pfizer, Roche, UCB, Grant/research support from: Honoraria for clinical trials from Abbvie, BMS and Novartis; Research Grants from Lilly, Peter Mandl Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Roche and UCB., Grant/research support from: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Roche and UCB., Philippe Carron Speakers bureau: AbbVie, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Gilead, Merck Sharp Dohme, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Gilead, Merck Sharp Dohme, Novartis, Pfizer, and UCB, Grant/research support from: Merck Sharp Dohme, Pfizer and UCB, Marina Backhaus Speakers bureau: BMS, Gilead, Jonsson, MSD, Novartis, Pfizer, Roche and UCB, Consultant of: BMS, Gilead, Jonsson, MSD, Novartis, Pfizer, Roche, UCB, Grant/research support from: BMS, Gilead, Jonsson, MSD, Novartis, Pfizer, Roche, UCB, Alejandra López-Rodríguez Speakers bureau: Eli Lilly, GSK, Janssen, Novartis, Roche and UCB, Consultant of: Eli Lilly, GSK, Janssen, Novartis, Roche and UCB, Petra Hanova: None declared, Punit Goyanka Employee of: Novartis, Braja Gopal Sahoo Employee of: Novartis, Corine Gaillez Shareholder of: Shareholder of Novartis and BMS, Employee of: Novartis, Weibin Bao Employee of: Novartis
Collapse
|
13
|
Felten R, Widawski L, Spielmann L, Gaillez C, Bao W, Gottenberg JE, Duret PM, Messer L. POS1065 IMPACT OF HYPERURICEMIA ON CLINICAL PHENOTYPE, COMORBIDITIES, AND RESPONSE TO SECUKINUMAB IN PSORIATIC ARTHRITIS: POST HOC ANALYSIS OF FUTURE AND MAXIMISE STUDIES. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundHyperuricemia (HU) is a metabolic abnormality associated with psoriasis (PsO) and psoriatic arthritis (PsA)1. The prevalence of HU is 2–13% in general population, 19–20% in PsO patients (pts), and 27–32% in PsA pts1,2. Pts with PsO/PsA are at significantly increased risk of HU and development of gout1. The pathogenic role of chronic HU in the development and maintenance of PsA is based on epidemiological, clinical, and fundamental arguments and hence does not appear fortuitous. These processes can influence each other3. Moreover, PsA with HU has been shown to be more peripheral, destructive, and challenging to treat4.ObjectivesTo evaluate the impact of HU on PsA in terms of clinical presentation, severity, comorbidities, and response to secukinumab (SEC) over 1-year.MethodsThis post hoc analysis included pooled data from PsA pts enrolled in the FUTURE 2–5 and MAXIMISE phase 3 trials. Pts were stratified into 2 groups based on baseline (BL) serum uric acid (SUA) level (HU: ≥360 µmol/L; without HU: <360 µmol/L and no history of gout and/or uric acid lowering therapies [ULT]). Demographic and disease characteristics, PsA and therapeutic history, and comorbidities data, were collected at BL. Evaluations included ACR20/50/70 responses, Psoriasis Area and Severity Index (PASI) 90 response, resolution of enthesitis and dactylitis, Health Assessment Questionnaire Disability Index (HAQ-DI), and mean change in SUA level, up to Week 52. All analyses were performed at a descriptive level and data presented as observed.ResultsOverall, 2504 PsA pts were included in the analysis, of which 822 (32.8%) had HU (62 [2.5%] with gout; 49 [2.0%] treated with ULT). At BL, pts with HU were mostly male (76.0% vs 34.2%) and had a higher body mass index (30.9 vs 28.3 kg/m2) with more comorbidities, such as hypertension (43.8% vs 31.3%), compared to pts without HU. A higher proportion of pts with HU had dactylitis (34.5% vs 25.9%), and PsO (48.3% vs 36.3%) with a greater mean PASI score (13.6 vs 10.2), compared to pts without HU (Table 1). The proportion of pts achieving ACR50, resolution of enthesitis/dactylitis, and mean change in HAQ-DI score were comparable up to Week 52 irrespective of BL HU status. The PASI90 response rate was higher in pts without HU with SEC 150 mg (with and without load) and similar in SEC 300 mg group irrespective of BL HU status (Figure 1).Table 1.Demographics and baseline characteristicsParameters, mean ± SD unless specifiedWith hyperuricemia (N=822)Without hyperuricemia (N=1682)Age (Years)48.5 ± 12.4148.3 ± 12.19Gender (Male), n (%)625 (76.0)576 (34.2)Weight (kg)92.71 ± 18.6279.59 ± 17.55BMI (kg/m2)30.90 ± 5.8628.33 ± 5.91History of hypertension, n (%)360 (43.8)526 (31.3)History of diabetes mellitus, n (%)85 (10.3)144 (8.6)TJC20.6 ± 15.5221.3 ± 16.25SJC10.9 ± 9.3110.8 ± 9.13Enthesitis, n (%)412 (50.1)852 (50.7)Dactylitis, n (%)284 (34.5)436 (25.9)Evidence of current psoriasis; n (%)397 (48.3)611 (36.3)Mean PASI score*13.61 ± 11.0310.16 ± 9.13TNFi naїve, n (%)477 (58.0)938 (55.8)MTX use at randomization, n (%)321 (39.1)685 (40.7)Serum uric acid (µmol/L)420.7 ± 57.11274.9 ± 51.98CRP (mg/L)11.6 ± 18.6610.7 ± 23.36*not collected in MAXMISEBMI, body mass index; CRP, C-reactive protein; MTX, methotrexate; SJC, swollen joint count; TJC, tender joint count; TNFi, tumor necrosis factor inhibitorConclusionIn this pooled analysis of SEC PsA studies, pts with HU reported a higher prevalence of hypertension, with more clinical dactylitis, and more PsO, with higher PASI score compared to pts without HU. Efficacy across all musculoskeletal manifestations was similar with SEC 150 and 300 mg; while PASI90 response rate was slightly better in patients without HU with SEC 150 mg, and similar with SEC 300 mg irrespective of HU status, at 1-year.References[1]Tripolino C, et al. Front Med. 2021;8:737573[2]AlJohani R, et al. J Rheumatol. 2018;45(2):213–7[3]Felten R, et al. Clin Rheumatol. 2020;39:1405–13[4]Widawski L, et al. Clin Rheumatol. 2022. https://doi.org/10.1007/s10067-022-06061-xDisclosure of InterestsRenaud FELTEN Consultant of: Novartis (Advisory board), Laura Widawski: None declared, Lionel Spielmann: None declared, Corine Gaillez Shareholder of: Novartis, Employee of: Novartis, Weibin Bao Shareholder of: Novartis, Employee of: Novartis, Jacques-Eric Gottenberg Consultant of: Novartis (Advisory board), Pierre-Marie Duret: None declared, Laurent Messer: None declared
Collapse
|
14
|
Feng X, Bao W, Wang X, Rao Q, Shi QL, Yue Z. [Pituicytoma: a clinicopathological analysis of twenty-one cases]. Zhonghua Bing Li Xue Za Zhi 2022; 51:314-318. [PMID: 35359042 DOI: 10.3760/cma.j.cn112151-20210818-00579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To investigate the clinicopathological features and treatment strategies of pituicytoma. Methods: Twenty-one cases of pituicytoma were collected at the First Affiliated Hospital of Nanjing Medical University and Jinling Hospital, Nanjing, China from 2009 to 2020. The clinical data of 21 pituicytoma patients was retrospectively analyzed, and the relevant literature was reviewed. Results: Twenty-one patients aged 4 to 68 years, including 8 males and 13 females. All patients underwent surgical treatment. Histologically, the tumor was consisted almost entirely of elongate, bipolar spindle cells arranged in a fascicular or storiform pattern. Mitotic figures were rare. Immunohistochemically, tumor cells were diffusely positive for S-100 protein (21/21), vimentin (15/15) and TTF1 (14/14), while they were weakly or focally positive for GFAP (13/16) and EMA (6/12). CKpan was negative in all cases and Ki-67 proliferation index was low (<5%). Among the 18 patients with follow-up, all survived and 2 relapsed after surgery. Conclusions: Pituicytoma is a rare low-grade glioma of the sellar area. It is easily confused with other sellar tumors. Preoperative diagnosis is difficult. It needs to be confirmed by histopathology and immunohistochemistry. Microsurgery is the main treatment method at present.
Collapse
Affiliation(s)
- X Feng
- Department of Pathology, Jinling Hospital, Nanjing 210002, China
| | - W Bao
- Department of Pathology, Jinling Hospital, Nanjing 210002, China
| | - X Wang
- Department of Pathology, Jinling Hospital, Nanjing 210002, China
| | - Q Rao
- Department of Pathology, Jinling Hospital, Nanjing 210002, China
| | - Q L Shi
- Department of Pathology, Jinling Hospital, Nanjing 210002, China
| | - Z Yue
- Department of Neurosurgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| |
Collapse
|
15
|
Han W, Wang N, Kong R, Bao W, Lu J. Ligand-activated PPARδ expression promotes hepatocellular carcinoma progression by regulating the PI3K-AKT signaling pathway. J Transl Med 2022; 20:86. [PMID: 35151320 PMCID: PMC8840031 DOI: 10.1186/s12967-022-03288-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Accepted: 01/31/2022] [Indexed: 11/22/2022] Open
Abstract
Background Peroxisome proliferator-activated receptor-beta/delta (PPARδ) was considered as the key regulator involved in the evolution of various tumors. Given that PPARδ potential role in hepatocellular carcinoma (HCC) is still obscure, we comprehensively assessed its expression pattern, prognosis, functions and correlation with tumor microenvironment in HCC using public database data and in vitro studies. Methods Transcriptional data and clinical data in the TCGA and GEO database were analyzed in R software. Quantitative real-time polymerase chain reaction (qRT-PCR), western blotting and immunohistochemistry were used to detect the expression level of related RNA and proteins. The malignant biological characteristics were explored by cell counting Kit-8 (CCK8), 5-Ethynyl-2ʹ-deoxyuridine (EdU) assay and wound healing assay. Results Our results illustrated that PPARδ expression was significantly higher in HCC tissues and HCC cell lines. Elevated expression of PPARδ suggested poor clinical staging and prognosis in HCC. Ligand-activated PPARδ expression promoted the proliferation and invasion of HCC cells via PDK1/AKT/GSK3β signaling pathway. The expression of PPARδ was closely related to the HCC tumor microenvironment. Conclusions PPARδ plays an important part in HCC progression, penetrating investigation of the related regulatory mechanism may shed light upon further biological and pharmacological value.
Collapse
|
16
|
Fallon M, Sopata M, Dragon E, Brown M, Viktrup L, West C, Hamlett K, Bao W, Agyemang A. LBA62 Efficacy and safety of tanezumab in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2143] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
17
|
Kong R, Wang N, Han W, Bao W, Lu J. IFNγ-mediated repression of system xc - drives vulnerability to induced ferroptosis in hepatocellular carcinoma cells. J Leukoc Biol 2021; 110:301-314. [PMID: 34318944 DOI: 10.1002/jlb.3ma1220-815rrr] [Citation(s) in RCA: 56] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 06/10/2021] [Accepted: 06/14/2021] [Indexed: 12/22/2022] Open
Abstract
IFNγ released from CD8+ T cells or natural killer cells plays a crucial role in antitumor host immunity. Several studies have found that IFNγ is involved in regulating tumor cell proliferation and apoptosis. However, few studies have examined its role in cell ferroptosis. Here, we found that IFNγ treatment enhanced glutathione depletion, promoted cell cycle arrested in G0/G1 phase, increased lipid peroxidation, and sensitized cells to ferroptosis activators. Additionally, IFNγ down-regulated the mRNA and protein levels of SLC3A2 and SLC7A11, two subunits of the glutamate-cystine antiporter system xc- via activating the JAK/STAT pathway in hepatocellular carcinoma (HCC) cell lines. Furthermore, IFNγ increased reactive oxygen species levels and decreased mitochondiral membrane potential in Bel7402 and HepG2 cells. These changes were accompanied by decreased system xc- activity. Cancer cells exposed to TGFβ1 for 48 h showed sensitization to IFNγ + erastin-induced ferroptosis, with decreased system xc- expression. In conclusion, IFNγ repressed system xc- activation via activating JAK/STAT signaling. Additionally, enhanced lipid peroxidation was associated with altered mitochondrial function in HCC cells. Our findings identified a role for IFNγ in sensitizing HCC cells to ferroptosis, which provided new insights for applying IFNγ as a cancer treatment.
Collapse
Affiliation(s)
- Rui Kong
- Department of Gastroenterology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Tongji University, School of Medicine, Shanghai, China
| | - Nan Wang
- Department of Gastroenterology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Tongji University, School of Medicine, Shanghai, China
| | - Wei Han
- Department of Gastroenterology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Tongji University, School of Medicine, Shanghai, China
| | - Wen Bao
- Department of Gastroenterology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Tongji University, School of Medicine, Shanghai, China
| | - Jie Lu
- Department of Gastroenterology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Tongji University, School of Medicine, Shanghai, China
| |
Collapse
|
18
|
Yang J, Zhang JW, Bao W, Qiu SQ, Li S, Xiang SH, Song J, Zhang J, Tan B. Chiral Phosphoric Acid-Catalyzed Remote Control of Axial Chirality at Boron-Carbon Bond. J Am Chem Soc 2021; 143:12924-12929. [PMID: 34384026 DOI: 10.1021/jacs.1c05079] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The previously elusive catalytic enantioselective construction of axially chiral B-aryl-1,2-azaborines with a C-B stereogenic axis has been realized through a chiral phosphoric acid-catalyzed desymmetrization strategy reported herein. The electrophilic aromatic substitution reaction of 3,5-disubsituted phenols with diazodicarboxamides could afford these axially chiral structures in good efficiency with excellent enantiocontrol. The efficient long-range stereochemical control is achieved by multiple well-defined H-bonding interactions between chiral phosphoric acid and both substrates. Meanwhile, the reaction duration could be markedly shortened with weakly acidic N-H in 1,2-azaborine acting as H-bond donor. The scalability of the reaction and facile cleavage of the N-N bond in the product further demonstrated the practicality of this method.
Collapse
Affiliation(s)
- Junxian Yang
- International Joint Research Center for Molecular Science, College of Chemistry and Environmental Engineering, College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China.,Shenzhen Grubbs Institute, Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China
| | - Ji-Wei Zhang
- Shenzhen Grubbs Institute, Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China
| | - Wen Bao
- Shenzhen Grubbs Institute, Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China
| | - Sheng-Qi Qiu
- International Joint Research Center for Molecular Science, College of Chemistry and Environmental Engineering, College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China.,Shenzhen Grubbs Institute, Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China
| | - Shaoyu Li
- Shenzhen Grubbs Institute, Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China.,Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen 518055, China
| | - Shao-Hua Xiang
- Shenzhen Grubbs Institute, Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China.,Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen 518055, China
| | - Jun Song
- International Joint Research Center for Molecular Science, College of Chemistry and Environmental Engineering, College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China
| | - Junmin Zhang
- International Joint Research Center for Molecular Science, College of Chemistry and Environmental Engineering, College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China
| | - Bin Tan
- Shenzhen Grubbs Institute, Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China
| |
Collapse
|
19
|
Peng J, Xiao Y, Li Y, Liang W, Sun H, Bao W, Huang Q, Zhang Y, Wu S. Testing the reliability and validity of the Experiences in Close Relationships Scale–Short Form with Chinese college students. soc behav pers 2021. [DOI: 10.2224/sbp.10400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Currently, there is no instrument to quickly measure adult attachment in the Chinese cultural context. In this study the Experiences in Close Relationships Scale–Short Form (ECR-S) was translated and tested in terms of reliability and validity with Chinese college students. All
items of the Chinese-version ECR-S showed high discriminability and the scale had a two-dimensional structure in both exploratory and confirmatory factor analyses. The internal consistency coefficients of the two subscales of the ECR-S showed excellent reliability, and scores were modestly
to highly correlated with the criteria of state adult attachment, self-esteem, anxiety, pressure, depression, and satisfaction with intimate (romantic) relationships. It can be concluded that the Chinese version of the ECR-S has high reliability and validity; thus, it meets the requirements
for psychometric tools and can be used to assess Chinese adults' attachment.
Collapse
|
20
|
Coates LC, Mease PJ, Gladman DD, Navarra S, Bao W, Gaillez C. POS1051 SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND INHIBITS STRUCTURAL DAMAGE IN PsA PATIENTS WITH SUSTAINED REMISSION OR LOW DISEASE ACTIVITY: RESULTS FROM A PHASE 3 STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Disease Activity Index for Psoriatic Arthritis (DAPSA) or the minimal disease activity (MDA) are considered for defining remission (REM) or low disease activity (LDA) in secukinumab (SEC) treated patients (pts) with PsA (Psoriatic Arthritis).1 Currently, limited SEC data are available on pts with PsA achieving sustained REM in clinical trials or real-world evidence, using these stringent criteria.Objectives:To report an exploratory analysis on achievement of sustained REM/LDA in pts with PsA treated with SEC and impact on structural outcomes, physical function and health-related quality of life (HRQoL) in the FUTURE 5 study (NCT02404350).Methods:FUTURE 5 is a randomised, double-blind, placebo-controlled 2-year phase 3 trial in pts with active PsA.2 Pts randomised to SEC 150 mg could be escalated to 300 mg from Week (Wk) 52 to 104, based on investigators’ judgement. The pts were categorised as either not achieving REM/LDA, achieving it once only or sustained REM/LDA, which was defined as pts who achieved REM/LDA between Wks 24-52 and maintained the same response at least 2 of the next 6 visits (visit every 8 Wks). Of pts who did not achieve REM/LDA, achieved REM/LDA (VLDA, DAPSA REM, MDA, DAPSA LDA+REM) between Wk 24 and 52, the relationship between absence of REM/LDA, REM/LDA, sustained REM/LDA, proportion of pts with non-radiographic progression (assessed using the van der Heijde [mTSS]), physical function (health assessment questionnaire disability index [HAQ-DI]), and short form-36 physical component score [SF-36 PCS])3 were assessed.Results:In total, 996 pts were randomised to one of 4 treatment groups: SEC 300 mg loading dose (LD; N=222), SEC 150 mg LD (N=220), SEC 150 mg no loading dose (NL; N=222), and placebo (N=332). The baseline clinical characteristics were comparable across treatment groups. Majority of pts could achieve either sustained MDA/sustained DAPSA LDA+REM (Figure 1). Pts achieving REM/LDA, whether at one visit or consistently, showed improved physical function and SF36-PCS at Wk 104.3A high proportion of pts did not show radiographic progression at Wk 104 irrespective of achievement of REM/LDA category (Table 1).Conclusion:The majority of patients treated with secukinumab were able to achieve sustained LDA. Sustained LDA/REM was associated with improved HRQoL, physical function and inhibition of structural damage progression.References:[1]Coates LC, et al. J Rheumatol. 2018;46(1):38–42.[2]Van der Heijde D, et al. Rheumatology. 2020;59(6):1325–1334.[3]Coates L, et al. [0353]. Arthritis Rheumatol. 2020;72 (suppl 10).Figure 1.Proportion of patients achieving VLDA/MDA/DAPSA REM/DAPSA REM+LDASus-tained REM/LDA was defined if the same response was achieved at least 2 out of the next 6 visits (every 8 weeks), respectively. DAPSA, Disease activity in Psoriatic Arthritis; LD, loading dose; LDA, Low Disease Activity; MDA, Minimal Disease Activity; N, number of randomised patients assessed at both Week 24 and 104; NL, without loading dose; REM, remission; SEC, secukinumab; VLDA, Very Low Disease ActivityTable 1.Percentage of vdH-mTSS no progression at Week 104 (change from baseline ≤0.5) by REM/LDA and sustained REM/LDA statusREM and LDA composite indices, n (%)Treatment groupNo REM/LDAREM/LDA only onceSustained REM/LDAMDASEC 150 mg LD64 (75.3)16 (80.0)76 (86.4)SEC 150 mg NL56 (75.7)15 (78.9)69 (82.1)SEC 300 mg LD58 (79.5)19 (95.0)100 (94.3)VLDASEC 150 mg LD108 (78.8)15 (83.3)30 (88.2)SEC 150 mg NL95 (75.4)13 (81.3)32 (91.4)SEC 300 mg LD 115 (84.6)17 (94.4)45 (100.0)DAPSA REMSEC 150 mg LD77 (76.2)11 (78.6)46 (92.0)SEC 150 mg NL65 (71.4)10 (76.9)50 (87.7)SEC 300 mg LD82 (83.7)14 (93.3)63 (96.9)DAPSA LDA + REMSEC 150 mg LD29 (70.7)16 (84.2)80 (84.2)SEC 150 mg NL23 (71.9)15 (75.0)79 (79.0)SEC 300 mg LD39 (88.6)21 (84.0)97 (89.0)Sustained REM/LDA was defined if the same response was achieved at least twice out of the next 6 visits (every 8 weeks), respectively. n, number of evaluable patients; vdH-mTSS, van der Heijde- modified total Sharp scoreDisclosure of Interests:Laura C Coates Consultant of: Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB, Grant/research support from: Abbvie, Celgene, Lilly, Novartis and Pfizer, Philip J Mease Speakers bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, BMS, Boehringer Ingelheim, Galapagos, Celgene, Genentech, Gilead, Janssen, Lilly, Novartis, Pfizer, SUN Pharma, and UCB, Grant/research support from: AbbVie, Amgen, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, SUN, and UCB, Dafna D Gladman Consultant of: Abbvie, Amgen, BMS, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer and UCB, Grant/research support from: Abbvie, Amgen, BMS, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer and UCB, Sandra Navarra Speakers bureau: Pfizer, Novartis, Astra-Zeneca, Janssen, Lilly, and Astellas, Consultant of: Pfizer, Novartis, Astra-Zeneca, Janssen, Lilly, and Astellas, Weibin Bao Shareholder of: Novartis, Employee of: Novartis, Corine Gaillez Shareholder of: Novartis and BMS, Employee of: Novartis.
Collapse
|
21
|
Goupille P, Behrens F, Coates LC, Gratacos-Masmitja J, Mease PJ, Gladman DD, Nash P, Kavanaugh A, Martin R, Bao W, Gaillez C, Mcinnes I. POS1044 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB ON ACR CORE COMPONENTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE EXCEED STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:EXCEED (NCT02745080) was the first fully blinded head-to-head trial to evaluate the efficacy and safety of secukinumab (SEC) versus (vs) adalimumab (ADA) monotherapy in patients with active psoriatic arthritis (PsA) with a primary endpoint of American College of Rheumatology (ACR) 20 at Week 52. Although SEC narrowly missed statistical significance for superiority vs ADA, numerically higher response for other musculoskeletal endpoints and composite indices were observed with SEC.1Objectives:To explore the effect of SEC and ADA on ACR core components, function and Health-related Quality of Life (HRQoL) outcomes.Methods:Patients were randomised 1:1 to receive SEC 300 mg (N=426) subcutaneous (s.c.) at baseline, Week 1-4, followed by every 4 weeks until Week 48 or ADA 40 mg (N=427) s.c. at baseline followed by same dosing every 2 weeks until Week 50. The primary, key secondary and some exploratory endpoints at Week 52 were previously reported.1 A supportive analysis for ACR50 response using logistic regression model and trimmed means model for Health Assessment Questionnaire-Disability Index (HAQ-DI) with gender and smoking status as factors was performed to adjust for imbalances in baseline characteristics. An exploratory analysis of ACR core components with SEC vs ADA at Week 52 was conducted using a mixed-effects repeated measures model that included tender and swollen joint counts, patient and physician global assessment, PsA pain (VAS) and erythrocyte sedimentation rate. HRQoL variables were also exploratory and assessed based on Short Form Health Survey Physical/Mental Component Summary (SF-36 PCS/MCS) scores and Dermatology Life Quality Index (DLQI).Results:The demographic and baseline disease characteristics were comparable across treatment groups, except for an imbalance in sex (females: 51.2% vs 46.4%) and smoking status (yes: 21.8% vs 17.8%) in SEC and ADA group, respectively. At Week 52, ACR50 responses were 49.0% and 44.8% (P=0.0929) and HAQ-DI mean change from baseline were −0.69 and −0.58 (P=0.0314) in SEC and ADA treatment groups, respectively after adjusting for gender and smoking status. No major difference across ACR core components was observed in both treatment groups at Week 52 (Table 1). At Week 52, SEC presented similar improvement in SF-36 PCS/MCS score and numerically higher improvement in DLQI compared to ADA (Figure 1).Conclusion:Secukinumab provided similar improvements in ACR core components and SF-36 based quality of life at Week 52 with adalimumab. Greater improvement in HAQ-DI response and DLQI was demonstrated with secukinumab compared to adalimumab.References:[1]McInnes IB, et al. Lancet. 2020; 395:1496–505.Table 1.ACR Core Components at Week 52VariablesSecukinumab 300 mg(N=426)Adalimumab 40 mg(N=427)P-valueBL, mean ± SELSM change from BL ± SEBL, mean ± SELSM change from BL ± SETender joint score(based on 78 joints)19.4 ± 13.86−14.27 ± 0.4420.6 ± 14.81−13.90 ± 0.450.5549Swollen joint score(based on 76 joints)9.7 ± 7.30−8.41 ± 0.1910.2 ± 7.86−8.06 ± 0.200.1962Patients global assessment64.0 ± 19.67−33.81 ± 1.1461.9 ± 20.75−31.61 ± 1.190.1825Physicians global assessment60.0 ± 17.12−46.24 ± 0.8061.4 ± 15.92−43.63 ± 0.840.0243Psoriatic arthritis pain (VAS)58.6 ± 23.49−30.21 ± 1.1857.9 ± 22.42−29.44 ± 1.230.6500Erythrocyte sedimentation rate (mm/h)23.8 ± 18.93−9.63 ± 0.6223.9 ± 17.99−9.28 ± 0.640.7029LS mean and nominal P-values are from a mixed-effects repeated measures model with treatment group, analysis visit as factors, weight and BL score as covariates, and by treatment and BL score as interaction terms, unstructured covariance structure. ACR, American College of Rheumatology; BL, baseline; LSM, least squares mean; N, total number of randomised patients; SE, standard error; VAS, visual analogue scaleFigure 1.HRQoL Analysis at Week 52Disclosure of Interests:Philippe Goupille Speakers bureau: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Janssen, Eli Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Consultant of: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Janssen, Eli Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Grant/research support from: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Janssen, Eli Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Frank Behrens Paid instructor for: Eli Lilly, Consultant of: Pfizer, AbbVie, Sanofi, Eli Lilly, Novartis, Genzyme, Boehringer Ingelheim, Janssen, MSD, Celgene, Roche and Chugai, Grant/research support from: Pfizer, Janssen, Chugai, Celgene and Roche, Laura C Coates Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Biogen, BMS, Celgene, Domain, Eli Lilly, Gilead, GSK, Janssen, Medac, Novartis, Pfizer, Serac and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Jordi Gratacos-Masmitja Speakers bureau: AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Novartis and Pfizer, Consultant of: AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Novartis and Pfizer, Grant/research support from: AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Novartis and Pfizer, Philip J Mease Speakers bureau: AbbVie, Amgen, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Galapagos, Celgene, Genentech, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, SUN Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Galapagos, Genentech, Gilead, Janssen, Eli Lilly, Merck, Novartis, Pfizer, SUN Pharma, and UCB, Dafna D Gladman Consultant of: Amgen, AbbVie, BMS, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer and UCB, Grant/research support from: Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Peter Nash Speakers bureau: Novartis, Abbvie, Roche, Pfizer, BMS, Janssen, Celgene, UCB, Eli Lilly, MSD, Sanofi, Gilead, Consultant of: Novartis, Abbvie, Roche, Pfizer, BMS, Janssen, Celgene, UCB, Eli Lilly, MSD, Sanofi, Gilead, Grant/research support from: Novartis, Abbvie, Roche, Pfizer, BMS, Janssen, Celgene, UCB, Eli Lilly, MSD, Sanofi, Gilead, Arthur Kavanaugh Consultant of: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, and UCB, Ruvie Martin Shareholder of: Novartis, Employee of: Novartis, Weibin Bao Shareholder of: Novartis, Employee of: Novartis, Corine Gaillez Shareholder of: Novartis and BMS, Employee of: Novartis, Iain McInnes Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, and UCB.
Collapse
|
22
|
Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CEM, Bao W, Pellet P, Pricop L, McInnes IB. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. Br J Dermatol 2021; 185:1124-1134. [PMID: 33913511 PMCID: PMC9291158 DOI: 10.1111/bjd.20413] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/22/2021] [Indexed: 11/28/2022]
Abstract
Background Secukinumab [an interleukin (IL)‐17A inhibitor] has demonstrated significantly higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL‐12/23 inhibitor) in patients with moderate‐to‐severe plaque psoriasis. Objectives To report 52‐week results from a prespecified analysis of patients with active psoriatic arthritis (PsA) having concomitant moderate‐to‐severe plaque psoriasis from the head‐to‐head EXCEED monotherapy study comparing secukinumab with adalimumab. Methods Patients were randomized to receive secukinumab 300 mg via subcutaneous injection at baseline, week 1–4, and then every 4 weeks until week 48 or adalimumab 40 mg via subcutaneous injection every 2 weeks from baseline until week 50. Assessments in patients with concomitant moderate‐to‐severe psoriasis, defined as having affected body surface area > 10% or Psoriasis Area and Severity Index (PASI) ≥ 10 at baseline, included musculoskeletal, skin and quality‐of‐life outcomes. Missing data were handled using multiple imputation. Results Of the 853 patients [secukinumab (N = 426), adalimumab (N = 427)], 211 (24·7%) had concomitant moderate‐to‐severe psoriasis [secukinumab (N = 110, 25·8%), adalimumab (N = 101, 23·7%)]. Up to week 50, 5·5% of patients discontinued secukinumab vs.17·8% in the adalimumab group. The proportion of patients who achieved American College of Rheumatology (ACR) 20 response was 76·4% with secukinumab vs. 68·3% with adalimumab (P = 0·175), PASI 100 response was 39·1% vs. 23·8% (P = 0·013), and simultaneous improvement in ACR 50 and PASI 100 response at week 52 was 28·2% vs. 17·7%, respectively (P = 0·06). Secukinumab demonstrated consistently higher responses vs. adalimumab across skin endpoints. Conclusions This prespecified analysis in PsA patients with concomitant moderate‐to‐severe plaque psoriasis in the EXCEED study provides further evidence that IL‐17 inhibitors offer a comprehensive biological treatment to manage the concomitant features of psoriasis and PsA.
What is already known about this topic?
Secukinumab, an interleukin‐17A inhibitor, has previously been reported to have significantly higher efficacy in head‐to‐head trials vs. etanercept and ustekinumab in patients with moderate‐to‐severe plaque psoriasis.
What does this study add?The results of the study provide valuable head‐to‐head data on the efficacy of two biologics with different mechanisms of action (secukinumab and adalimumab) as first‐line biological monotherapy for patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis. The findings of this study can further help physicians to make informed and evidence‐based decisions for the treatment of patients with active psoriatic arthritis who have concomitant moderate‐to‐severe plaque psoriasis.
Linked Comment: E. Sbidian and L. Pina‐Vegas. Br J Dermatol 2021; 185:1085.
Collapse
Affiliation(s)
- A B Gottlieb
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - J F Merola
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - K Reich
- Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg- Eppendorf, Hamburg, Germany
| | - F Behrens
- Rheumatology University Hospital and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine and Pharmacology TMP and Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, Goethe University, Frankfurt, Germany
| | - P Nash
- Department of Medicine, Griffith University, Brisbane, QLD, Australia
| | - C E M Griffiths
- The Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, UK
| | - W Bao
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | - P Pellet
- Novartis Pharma AG, Basel, Switzerland
| | - L Pricop
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | | |
Collapse
|
23
|
Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W, Jehl V, Marfo K, Primatesta P, Shete A, Trivedi V, Mease PJ. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol 2021; 185:935-944. [PMID: 33829482 DOI: 10.1111/bjd.20136] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/06/2021] [Indexed: 11/29/2022]
Abstract
BACKGROUND Data on the use of biologic therapy and malignancy risk are inconsistent due to limited long-term robust studies. OBJECTIVES To assess the malignancy risk in patients with secukinumab-treated psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS). METHODS This integrated safety analysis from both the secukinumab clinical trial programme and postmarketing safety surveillance data included any patient receiving at least one approved dose of secukinumab with a maximum of 5 years of follow-up. Safety analyses evaluated the rate of malignancy using exposure-adjusted incidence rates [EAIR; incidence rates per 100 patient treatment-years (PTY)]. Standardized incidence ratios (SIRs) were reported using the Surveillance, Epidemiology, and End Results Program (SEER) database as a reference population. Crude incidence of malignancy was also reported using postmarketing surveillance data. RESULTS Safety data from 49 clinical trials with secukinumab-treated patients were included: 10 685 patients with psoriasis, 2523 with PsA and 1311 with AS. Across indications over a 5-year period, the EAIR of malignancy was 0·85 per 100 PTY [95% confidence interval (CI) 0·74-0·98] in secukinumab-treated patients, corresponding to 204 patients per 23 908 PTY. Overall, the observed vs. expected number of malignancies from secukinumab clinical trial data were comparable, as indicated by an SIR of 0·99 (95% CI 0·82-1·19) across indications. The estimated crude cumulative incidence reporting rate per 100 PTY for malignancy was 0·27 in the postmarketing surveillance data across indications with a cumulative exposure of 285 811 PTY. CONCLUSIONS In this large safety analysis, the risk of malignancy was low for up to 5 years of secukinumab treatment. These data support the long-term use of secukinumab in these indications.
Collapse
Affiliation(s)
- M Lebwohl
- Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - A Deodhar
- Oregon Health & Science University, Portland, OR, USA
| | - C E M Griffiths
- The Dermatology Centre, The University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, UK
| | - M A Menter
- Division of Dermatology, Baylor Scott & White Health, Dallas, TX, USA
| | - D Poddubnyy
- Division of Gastroenterology, Infectious Diseases and Rheumatology, Charité, Universitätsmedizin Berlin, Germany, and Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany
| | - W Bao
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | - V Jehl
- Novartis Pharma AG, Basel, Switzerland
| | - K Marfo
- Novartis Pharma AG, Basel, Switzerland
| | | | - A Shete
- Novartis Pharma AG, Basel, Switzerland
| | - V Trivedi
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | - P J Mease
- Department of Rheumatology, Swedish Health Services/Providence St Joseph Health and University of Washington, Seattle, WA, USA
| |
Collapse
|
24
|
Feng Q, Ma X, Bao W, Li SJ, Lan Y, Song Q. Catalytic Atroposelective Catellani Reaction Enables Construction of Axially Chiral Biaryl Monophosphine Oxides. CCS Chem 2021. [DOI: 10.31635/ccschem.021.202000725] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Qiang Feng
- Institute of Next Generation Matter Transformation, College of Chemical Engineering, College of Material Sciences Engineering, Huaqiao University, Xiamen 361021
| | - Xingxing Ma
- Key Laboratory of Molecule Synthesis and Function Discovery, College of Chemistry, Fuzhou University, Fuzhou 350108
| | - Wen Bao
- School of Pharmacy, State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000
| | - Shi-Jun Li
- Green Catalysis Center, College of Chemistry, Zhengzhou University, Zhengzhou 450001
| | - Yu Lan
- Green Catalysis Center, College of Chemistry, Zhengzhou University, Zhengzhou 450001
- School of Chemistry and Chemical Engineering, Chongqing Key Laboratory of Theoretical and Computational Chemistry, Chongqing University, Chongqing 400030
| | - Qiuling Song
- Institute of Next Generation Matter Transformation, College of Chemical Engineering, College of Material Sciences Engineering, Huaqiao University, Xiamen 361021
- Key Laboratory of Molecule Synthesis and Function Discovery, College of Chemistry, Fuzhou University, Fuzhou 350108
| |
Collapse
|
25
|
Li H, He J, Bao W, Wang P, Lv Y, Xu C, Hu P, Gao Y, Zheng S, An J, Deng G, Dong J. Key points of technical review for the registration of SARS-CoV-2 antigen/antibody tests. Bioanalysis 2021; 13:77-88. [PMID: 33427483 PMCID: PMC7814677 DOI: 10.4155/bio-2020-0219] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2020] [Accepted: 12/02/2020] [Indexed: 12/16/2022] Open
Abstract
Coronavirus disease-2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally since its first report and become a worldwide pandemic. In response to the outbreak of COVID-19, Center for Medical Device Evaluation, NMPA (CMDE) initiated emergency review and approval procedures to accelerate the process of reviewing emergent medical products and issued the Key Points of Technical Review for the Registration of SARS-CoV-2 Antigen/Antibody Tests (Key Points) to provide the requirements on the technical review of the tests. With uncontrolled spread and evolution of COVID-19 in the world, continuous prevention and measurements are necessary for fighting this pandemic and SARS-CoV-2 antigen/antibody tests are still urgently needed. This article is an attempt to expand clarification of the Key Points to wider audiences based on current understanding of SARS-CoV-2 to facilitate the development and application of SARS-CoV-2 antigen/antibody tests.
Collapse
Affiliation(s)
- Hongran Li
- Center for Medical Device Evaluation, NMPA, Building 1, No. 50 Qixiang Road, Haidian District, Beijing 100081, PR China
| | - Jingyun He
- Center for Medical Device Evaluation, NMPA, Building 1, No. 50 Qixiang Road, Haidian District, Beijing 100081, PR China
| | - Wen Bao
- Center for Medical Device Evaluation, NMPA, Building 1, No. 50 Qixiang Road, Haidian District, Beijing 100081, PR China
| | - Peirong Wang
- Center for Medical Device Evaluation, NMPA, Building 1, No. 50 Qixiang Road, Haidian District, Beijing 100081, PR China
| | - Yunfeng Lv
- Center for Medical Device Evaluation, NMPA, Building 1, No. 50 Qixiang Road, Haidian District, Beijing 100081, PR China
| | - Chao Xu
- Center for Medical Device Evaluation, NMPA, Building 1, No. 50 Qixiang Road, Haidian District, Beijing 100081, PR China
| | - Peng Hu
- Center for Medical Device Evaluation, NMPA, Building 1, No. 50 Qixiang Road, Haidian District, Beijing 100081, PR China
| | - Yu Gao
- Center for Medical Device Evaluation, NMPA, Building 1, No. 50 Qixiang Road, Haidian District, Beijing 100081, PR China
| | - Shengwei Zheng
- Center for Medical Device Evaluation, NMPA, Building 1, No. 50 Qixiang Road, Haidian District, Beijing 100081, PR China
| | - Juanjuan An
- Center for Medical Device Evaluation, NMPA, Building 1, No. 50 Qixiang Road, Haidian District, Beijing 100081, PR China
| | - Gang Deng
- Center for Medical Device Evaluation, NMPA, Building 1, No. 50 Qixiang Road, Haidian District, Beijing 100081, PR China
| | - Jinchun Dong
- Center for Medical Device Evaluation, NMPA, Building 1, No. 50 Qixiang Road, Haidian District, Beijing 100081, PR China
| |
Collapse
|
26
|
Wang XX, Wei X, Wang X, Ma HH, Rao Q, Bao W. [Pancreatic hamartoma: report of a case]. Zhonghua Bing Li Xue Za Zhi 2020; 49:847-849. [PMID: 32746557 DOI: 10.3760/cma.j.cn112151-20191127-00761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- X X Wang
- Department of Pathology, General Hospital of Eastern Theater Command, Nanjing 210002, China
| | - X Wei
- Department of Pathology, General Hospital of Eastern Theater Command, Nanjing 210002, China
| | - X Wang
- Department of Pathology, General Hospital of Eastern Theater Command, Nanjing 210002, China
| | - H H Ma
- Department of Pathology, General Hospital of Eastern Theater Command, Nanjing 210002, China
| | - Q Rao
- Department of Pathology, General Hospital of Eastern Theater Command, Nanjing 210002, China
| | - W Bao
- Department of Pathology, General Hospital of Eastern Theater Command, Nanjing 210002, China
| |
Collapse
|
27
|
Bao W, Wang N, He Z. Synthesis of reduced C,N-TiO 2 for catalytic oxidation of HCHO indoors. J COORD CHEM 2020. [DOI: 10.1080/00958972.2020.1798416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Wen Bao
- Green Catalysis Center and College of Chemistry, Zhengzhou University, Zhengzhou, China
| | - Nan Wang
- Green Catalysis Center and College of Chemistry, Zhengzhou University, Zhengzhou, China
| | - Zhanhang He
- Green Catalysis Center and College of Chemistry, Zhengzhou University, Zhengzhou, China
| |
Collapse
|
28
|
Deodhar A, Mcinnes I, Baraliakos X, Reich K, Gottlieb AB, Lebwohl M, Schreiber S, Bao W, Marfo K, Richards H, Pricop L, Shete A, Safi J, Mease PJ. FRI0272 SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.5118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Pooled safety data has been reported with secukinumab (SEC) in patients (pts) with Psoriatic arthritis (PsA), Ankylosing Spondylitis (AS) and Psoriasis (PsO).1Objectives:To report longer-term safety data of SEC treatment in PsA, AS, PsO pts up to 5 years.Methods:The integrated clinical trial safety dataset included data pooled from 28 randomised controlled clinical trials of SEC 300 or 150 or 75 mg in PsO (11 Phase 3 and 8 Phase 4 trials), PsA (5 Phase 3 trials), and AS (4 Phase 3 trials), along with post-marketing safety surveillance data with a cut-off date of 25 December 2018. Adverse events (AEs) were reported as exposure-adjusted incident rates (EAIRs) per 100 pt-years. Analyses included all pts who received ≥1 dose of SEC.Results:A total of 12637 pts (8819, 2678 and 1140 pts with PsO, PsA and AS, with an exposure of 15063.1, 5984.6 and 3527.2 pt-years, respectively) were included. The most frequent AE was upper respiratory tract infection and EAIR per 100 pt-years for IBD, malignancies and MACE remained low. The EAIR per 100 pt-years for adverse events (AEs) of special interest are reported in Table 1. The cumulative post-marketing exposure to SEC was estimated to be ~285,811 pt-years across the approved indications. Safety data from post-marketing surveillance are reported in Table 2.Table 1.Selected AEs of interest with SEC across pooled clinical trialsVariablePsOPsAASSECN=8819SECN=2678SECN=1140Exposure (Days), Mean (SD)623.9 (567.7)816.2 (580.7)1130.1 (583.0)Death, n (%)15 (0.2)13 (0.5)10 (0.9)Selected AE’s of interest, EAIR (95% CI)Serious infections11.4 (1.2, 1.6)1.8 (1.5, 2.2)1.2 (0.9, 1.6)Candidainfections22.9 (2.7, 3.2)1.5 (1.2, 1.9)0.7 (0.5, 1.1)IBD3Crohn’s disease3Ulcerative colitis30.01 (0.0, 0.05)0.1 (0.05, 0.2)0.1 (0.08, 0.2)0.03 (0.0, 0.1)0.1 (0.04, 0.2)0.1 (0.04, 0.2)0.03 (0.0, 0.2)0.4 (0.24, 0.7)0.2 (0.1, 0.5)MACE40.4 (0.31, 0.5)0.4 (0.3, 0.6)0.7 (0.4, 1.0)Uveitis30.01 (0.0, 0.05)0.1 (0.04, 0.2)1.2 (0.9, 1.7)Malignancy50.9 (0.7, 1.0)1.0 (0.77, 1.3)0.5 (0.3, 0.8)1Rates for system organ class;2Rates for high level term;3Rates for preferred term (PT; IBD for unspecified IBD);4Rates for Novartis MedDRA Query term;5Rates for standardized MedDRA query term – ‘malignancies and unspecified tumour’; EAIR, exposure adjusted incidence rate per 100 pt-years; N, number of pts in the analysisTable 2.Summary of SEC post-marketing safetyExposure (PTY)PSUR126Dec14 -25Jun15PSUR226 Jun - 25Dec15PSUR326Dec15 -25Jun16PSUR426Jun -25Dec16PSUR526Dec16 -25Dec17PSUR626Dec17 -25Dec18Cumulative18387450168712854993744137325285811 n (Reporting rate PTY)Serious infections89 (4.8)149 (2.0)232 (1.4)475 (1.7)649 (0.7)1841 (1.3)3980 (1.4)Malignancy2 (0.1)15 (0.2)21 (0.1)50 (0.2)225 (0.2)422 (0.3)788 (0.3)Total IBD4 (0.2)12 (0.2)37(0.2)46 (0.2)185 (0.2)340 (0.3)693 (0.2)MACE6 (0.3)15 (0.2)16 (0.1)39 (0.1)151 (0.2)238 (0.2)504 (0.2)PSUR, periodic safety update report; PTY, pt-treatment yearsConclusion:In this long-term analysis across clinical trials and post-marketing surveillance, of pts with PsO, PsA and AS, SEC was well tolerated, with a safety profile consistent with previous reports.1Reference:[1]Deodhar et al. Arthritis Research & Therapy (2019) 21:111.Disclosure of Interests:Atul Deodhar Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB, Xenofon Baraliakos Grant/research support from: Grant/research support from: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Consultant of: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Speakers bureau: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Kristian Reich Grant/research support from: Affibody; Almirall; Amgen; Biogen; Boehringer Ingelheim; Celgene; Centocor; Covagen; Eli Lilly; Forward Pharma; Fresenius Medical Care; GlaxoSmithKline; Janssen; Kyowa Kirin; LEO Pharma; Medac; Merck; Novartis; Miltenyi Biotec; Ocean Pharma; Pfizer; Regeneron; Samsung Bioepis; Sanofi Genzyme; Takeda; UCB; Valeant and Xenoport., Consultant of: Affibody; Almirall; Amgen; Biogen; Boehringer Ingelheim; Celgene; Centocor; Covagen; Eli Lilly; Forward Pharma; Fresenius Medical Care; GlaxoSmithKline; Janssen; Kyowa Kirin; LEO Pharma; Medac; Merck; Novartis; Miltenyi Biotec; Ocean Pharma; Pfizer; Regeneron; Samsung Bioepis; Sanofi Genzyme; Takeda; UCB; Valeant and Xenoport., Speakers bureau: Affibody; Almirall; Amgen; Biogen; Boehringer Ingelheim; Celgene; Centocor; Covagen; Eli Lilly; Forward Pharma; Fresenius Medical Care; GlaxoSmithKline; Janssen; Kyowa Kirin; LEO Pharma; Medac; Merck; Novartis; Miltenyi Biotec; Ocean Pharma; Pfizer; Regeneron; Samsung Bioepis; Sanofi Genzyme; Takeda; UCB; Valeant and Xenoport., Alice B Gottlieb Grant/research support from:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Consultant of:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Speakers bureau:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Mark Lebwohl Grant/research support from: AbbVie, Amgen, Arcutis, AstraZeneca, Boehringer Ingelheim, Celgene, Clinuvel, Eli Lilly, Incyte, Janssen Research & Development, LLC, Kadmon Corp., LLC, Leo Pharmaceutucals, Medimmune, Novartis, Ortho Dermatologics, Pfizer, Sciderm, UCB, Inc., and ViDac, Consultant of: Allergan, Almirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Theravance, and Verrica, Stefan Schreiber Consultant of: AbbVie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist and Falk, Weibin Bao Shareholder of: Novartis, Employee of: Novartis, Kwaku Marfo Shareholder of: Novartis, Employee of: Novartis, Hanno Richards Shareholder of: Novartis, Employee of: Novartis, Luminita Pricop Shareholder of: Novartis, Employee of: Novartis, Abhijit Shete Shareholder of: Novartis, Employee of: Novartis, Jorge Safi Shareholder of: Novartis, Employee of: Novartis, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau
Collapse
|
29
|
Bao W, Gao ZP, Jin DP, Xue CG, Liang H, Lei LS, Xu XT, Zhang K, Wang SH. Direct synthesis of 2-substituted benzonitriles via alkylcyanation of arynes with N,N-disubstituted aminomalononitriles. Chem Commun (Camb) 2020; 56:7641-7644. [DOI: 10.1039/d0cc01591a] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
An efficient alkylcyanation of in situ generated arynes by N,N-disubstituted aminomalononitriles is described, enabling the direct synthesis of 2-substituted benzonitriles.
Collapse
Affiliation(s)
- Wen Bao
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Zhu-Peng Gao
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Da-Ping Jin
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Cao-Gen Xue
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Huan Liang
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Ling-Sheng Lei
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Xue-Tao Xu
- School of Biotechnology and Health Science
- Wuyi University
- Jiangmen 529020
- P. R. China
| | - Kun Zhang
- School of Biotechnology and Health Science
- Wuyi University
- Jiangmen 529020
- P. R. China
| | - Shao-Hua Wang
- School of Pharmacy & State Key Laboratory of Applied Organic Chemistry
- Lanzhou University
- Lanzhou 730000
- P. R. China
- School of Biotechnology and Health Science
| |
Collapse
|
30
|
Yang L, Feng H, Liu Y, Liu Z, Wang S, Dong L, Huo Y, Bao W. Influence of bamboo vinegar powder supplementation on growth performance, apparent digestibility and expression of growth-related genes in finishing pigs. ANIM NUTR FEED TECHN 2020. [DOI: 10.5958/0974-181x.2020.00017.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
31
|
Pascual-Figal D, Bao W, Senni M, Wachter R, Behlolavek J, Chakrabarti A, Noe A, Schwende H, Butylin D, Prescott M. 1410Clinical predictors of NT-proBNP response to early initiation of sacubitril/valsartan after hospitalisation for decompensated heart failure: An analysis of the TRANSITION study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0058] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
NT-proBNP has diagnostic and prognostic value in patients with heart failure (HF). Compared with enalapril, sacubitril/valsartan (S/V) significantly reduced NT-proBNP within 1 week (wk) of administration and reduced HF re-hospitalisation in patients with acute decompensated HF (ADHF) in PIONEER-HF. Identification of predictors of NT-proBNP reduction with S/V could aid prognostication following hospitalisation.
Methods
TRANSITION (NCT02661217) is an open label study in stabilised ADHF patients with HFrEF that compared S/V initiation pre- versus post-discharge (within 2 wk of discharge). Baseline NT-proBNP was measured at randomisation in both S/V groups (n=950). Clinical predictors of favourable response of NT-proBNP to S/V therapy (defined as reduction to <1000 pg/ml or >30% reduction vs. baseline) were studied at discharge, 4 wk and 10 wk post-randomisation.
Results
Median NT-proBNP at randomisation was similar in patients with S/V started pre- and post-discharge (1919 vs 1659 pg/ml). In patients receiving S/V in-hospital, NT-proBNP was reduced by 28% at discharge, compared to a 3% reduction in patients receiving optimised standard of care (between group p<0.001). A favorable response was reached in 46% vs 18% patients at discharge, 46% vs 42% at 4 weeks and 51% vs 48% at 10 weeks in pre- vs post-discharge groups. (Figure 1). Predictors of favourable NT-proBNP response to S/V at discharge were hypertension and shorter time from admission to first S/V dose. At 4 wk after randomisation, NT-proBNP was reduced similarly in patients started on S/V pre- and post-discharge. When the two S/V initiation groups were combined, predictors of favorable NT-proBNP response at 4 wk were higher initial dose of S/V (≥49/51 mg b.i.d.), higher baseline levels of NT-proBNP, de novo HF hospitalisation, ACEI/ARB naïve, lower baseline creatinine, no atrial fibrillation (AFib), no prior myocardial infarction (MI). A further reduction in NT-proBNP was seen at 10 wk post-randomisation in patients started on S/V pre- and post-discharge (38% vs 34%, between group p=0.250). Predictors of favourable NT-proBNP response to S/V were similar at 4 wk and 10 wk post-randomisation.
Conclusion
In-hospital initiation of sacubitril/valsartan shortly after stabilisation was associated with a prompt improvement of NT-proBNP already at discharge, whereas higher baseline levels of NT-proBNP, higher starting dose, absence of AFib and MI history, de novo HF and ACEI/ARB naïve status were associated with favourable NT-proBNP response in the vulnerable phase after discharge.
Acknowledgement/Funding
The TRANSITION study was funded by Novartis
Collapse
Affiliation(s)
| | - W Bao
- Novartis Pharmaceuticals, East Hanover, United States of America
| | - M Senni
- Ospedale Papa Giovanni XXIII, Heart Failure and Transplant Unit, Bergamo, Italy
| | - R Wachter
- Leipzig University Hospital, Leipzig, Germany
| | | | | | - A Noe
- Novartis Pharma AG, Basel, Switzerland
| | | | - D Butylin
- Novartis Pharma AG, Basel, Switzerland
| | - M Prescott
- Novartis Pharmaceuticals, East Hanover, United States of America
| |
Collapse
|
32
|
Wachter R, Pascual-Figal D, Belohlavek J, Straburzynska-Migaj E, Witte KK, Fonseca C, Cavusoglu Y, Pouleur AC, Goncalvesova E, Lonn E, Noe A, Schwende H, Bao W, Butylin D, Senni M. P773Initiation of sacubitril/valsartan and optimisation of evidence-based heart failure therapies after hospitalisation for acute decompensated heart failure: An analysis of the TRANSITION study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Optimisation of chronic heart failure (HF) therapy remains the key strategy to improve outcomes after hospitalisation for acute decompensated HF (ADHF) with reduced ejection fraction (HFrEF). Initiation and uptitration of disease-modifying therapies is challenging in this vulnerable patient population. We aimed to describe the patterns of treatment optimisation including sacubitril/valsartan (S/V) in the TRANSITION study.
Methods
TRANSITION (NCT02661217) was a randomised, open-label study comparing S/V initiation pre- vs. post-discharge (1–14 days) in patients admitted for ADHF after haemodynamic stabilisation. The primary endpoint was the proportion of patients achieving 97/103 mg S/V twice daily (bid) at 10 weeks post-randomisation. Up-titration of S/V was as per label. Information on dose of S/V and on the use of concomitant HF medication was collected at each study visit up to week 26.
Results
A total of 493 patients received at least one dose of S/V in the pre-discharge arm and 489 patients in the post-discharge arm. One month after randomisation, 45% of patients in the pre-d/c arm vs. 44% in the post-discharge arm used 24/26 mg bid starting dose and 42% vs. 40% were on 49/51 mg S/V bid, respectively. At week 10, 47% of patients had achieved the target dose in the pre-discharge arm vs. 51% in the post-discharge arm. At the end of the follow-up at 26 weeks, the proportion of patients on S/V target dose further increased to 53% in the pre-discharge and 61% in the post-discharge arm (Figure 1). At week 10, the mean dose of S/V was 132 mg in the pre-discharge arm and 136 mg in the post-discharge arm, and at week 26, it was 140 mg and 147 mg, respectively.
Before hospital admission, 52% and 54% of the patients received a beta-blocker (BB) in the pre-discharge and post-discharge group, respectively, and 42% in both arms received a mineralcorticoid receptor antagonist (MRA). At time of discharge, 68% and 71%% of the patients received a BB and 68% and 65% an MRA, in the pre-discharge and post-discharge groups, respectively. These proportions remained stable to week 10 and week 26.
Uptitration of sacubitril/valsartan
Conclusions
In the vulnerable post-ADHF population, initiation of S/V and up-titration to target dose was feasible within 10 weeks in half of the patients alongside with a 20% increase in the use of other disease-modifying medications that remained stable through the end of the 6-month follow-up.
Acknowledgement/Funding
The TRANSITION study was funded by Novartis
Collapse
Affiliation(s)
- R Wachter
- Leipzig University Hospital, Leipzig, Germany
| | | | | | | | - K K Witte
- University of Leeds, Leeds, United Kingdom
| | - C Fonseca
- Hospital de Sao Francisco Xavier, Lisbon, Portugal
| | - Y Cavusoglu
- Eskisehir Osmangazi University, Eskisehir, Turkey
| | | | - E Goncalvesova
- The National Institute of Cardiovascular Diseases, Bratislava 37, Slovakia
| | - E Lonn
- Hamilton Health Sciences General Site, Hamilton, Canada
| | - A Noe
- Novartis Pharma AG, Basel, Switzerland
| | | | - W Bao
- Novartis Pharmaceuticals, East Hanover, United States of America
| | - D Butylin
- Novartis Pharma AG, Basel, Switzerland
| | - M Senni
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
33
|
Pascual-Figal D, Witte KK, Wachter R, Belohlavek J, Straburzynska-Migaj E, Fonseca C, Cavusoglu Y, Pouleur AC, Mueller C, Lonn E, Noe A, Schwende H, Bao W, Butylin D, Senni M. P1637Rehospitalisations during 26 weeks of follow up from initiation of sacubitril/valsartan after acute decompensated heart failure: An analysis of the TRANSITION study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Patients with acute decompensated heart failure (ADHF) are at high risk of recurrent hospitalisations and death. In-hospital initiation of sacubitril/valsartan (S/V) reduced the risk for HF re-hospitalisation by 44% compared to enalapril in the PIONEER-HF study during the 8-week follow-up period. We aimed to describe the pattern of readmissions and their causes in the TRANSITION study, which randomised participants to pre-discharge or post-discharge initation of S/V.
Methods
TRANSITION (NCT02661217) was a randomised, open-label study comparing S/V initiation pre- vs. post-discharge (1–14 days) in haemodynamically stabilised patients with HF with reduced ejection fraction, admitted for ADHF. The primary endpoint was the proportion of patients achieving 97/103 mg S/V twice daily at 10 weeks post-randomisation. Information on rehospitalisation was collected throughout the study up to 26 weeks.
Results
A total of 493 patients received S/V in the pre-discharge arm and 489 patients in the post-discharge arm. Readmissions due to any cause were reported in 9.7% and 18.1% in the pre-discharge arm vs. 10.6% and 21.3% in the post-discharge arm within 30 days, and 10 weeks respectively. During the 26-weeks follow-up, all-cause readmission was reported in 34.5% of patients in the pre-discharge arm vs. 34.6% in the post-discharge arm. Median time to first rehospitalisation was 67 days in the pre-discharge arm (IQR: 26–110 days) and 50 days (IQR: 23–108 days) in the post-discharge arm. At least one HF hospitalisation was reported in 7.5% of patients in the pre-discharge arm and 7.4% in the post-discharge arm during 10 weeks and in 11.8% and 12.3% of patients, respectively, during 26 weeks of follow-up. Median duration of HF readmission was 7 days (IQR: 4–11 days) in the pre-discharge group and 6.5 days (IQR: 6.5–10 days) in the post-discharge arm. In total 2.6% and 5.5% patients in pre-discharge arm and 3.9% and 7% in the post-discharge arm visited an emergency room during 10 weeks and 26 weeks, respectively.
Conclusions
Initiation of S/V in patients hospitalised for ADHF either before or shortly after discharge, results in comparable rates of all cause and HF rehospitalisations, as well as emergency room visits without hospital admission over the 26 week follow-up period. HF re-hospitalisations rates at 10 weeks in TRANSITION are in line with the 8% in S/V arm reported in PIONEER-HF during the 8-weeks follow-up.
Acknowledgement/Funding
The TRANSITION study was funded by Novartis
Collapse
Affiliation(s)
| | - K K Witte
- University of Leeds, Leeds, United Kingdom
| | - R Wachter
- Leipzig University Hospital, Leipzig, Germany
| | | | | | - C Fonseca
- Hospital de Sao Francisco Xavier, Lisbon, Portugal
| | - Y Cavusoglu
- Eskisehir Osmangazi University, Eskisehir, Turkey
| | | | - C Mueller
- University Hospital Basel, Basel, Switzerland
| | - E Lonn
- Hamilton Health Sciences, Hamilton, Canada
| | - A Noe
- Novartis Pharma AG, Basel, Switzerland
| | | | - W Bao
- Novartis Pharmaceuticals, East Hanover, United States of America
| | - D Butylin
- Novartis Pharma AG, Basel, Switzerland
| | - M Senni
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
34
|
Bao W, Ma H, Wang N, He Z. pH‐sensitive carbon quantum dots−doxorubicin nanoparticles for tumor cellular targeted drug delivery. POLYM ADVAN TECHNOL 2019. [DOI: 10.1002/pat.4696] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Wen Bao
- The College of Chemistry and Molecular EngineeringZhengzhou University Zhengzhou China
| | - Haibo Ma
- The College of Chemistry and Molecular EngineeringZhengzhou University Zhengzhou China
| | - Nan Wang
- The College of Chemistry and Molecular EngineeringZhengzhou University Zhengzhou China
| | - Zhanhang He
- The College of Chemistry and Molecular EngineeringZhengzhou University Zhengzhou China
| |
Collapse
|
35
|
Shi Y, Bo Z, Pang G, Qu X, Bao W, Yang L, Ma Y. MiR-99a-5p regulates proliferation, migration and invasion abilities of human oral carcinoma cells by targeting NOX4. Neoplasma 2019; 64:666-673. [PMID: 28592118 DOI: 10.4149/neo_2017_503] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Previous research has showed that miR-99a-5p was a tumor suppressor. The aim of our study was to explore the effect of miR-99a-5p on the vitality and proliferation, migration together with the invasion of oral tumor cells via inhibiting the expression of NOX4. QRT-PCR and Western blot were applied to examine the expression level of miR-99a-5p and NOX4 in human oral tumorous and adjacent tissues. Dual luciferase reporter gene assay was applied to confirm that miR-99a-5p negatively regulated directly on NOX4 in TSCC1 cells. Cell transfection and lentiviral vectors were used to up-regulate expression of miR-99a-5p and NOX4, respectively. Cell proliferation, cell cycle, apoptosis and invasion along with the migration in different groups were assessed using MTT assay, colony formation assay, the flow cytometry, transwell assay and the wound healing assay, respectively. MiR-99a-5p was under-expressed in human oral tumor, while NOX4 was over-expressed. There was a negative relationship between miR-99a-5p and NOX4. Up-regulating miR-99a-5p or down-regulating NOX4 suppressed the vitality, proliferation, migration together with invasion of TSCC1 cells. MiR-99a-5p affected the vitality and proliferation, migration together with the invasion of oral tumor cells through targeting NOX4.
Collapse
|
36
|
Bao W, Liu R, Xia G, Wang F, Chen B. Applications of daunorubicin-loaded PLGA-PLL-PEG-Tf nanoparticles in hematologic malignancies: an in vitro and in vivo evaluation. Drug Des Devel Ther 2019; 13:1107-1115. [PMID: 31040647 PMCID: PMC6459145 DOI: 10.2147/dddt.s195832] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background With the development of drug delivery, novel tools and technological approaches have captured the attention of researchers in recent years. Several target drug delivery systems (DDSs) including nanoparticles (NPs) have been developed as an important strategy to deliver classical medicine. Objective The objective of this study was to evaluate the application of novel daunorubicin (DNR)-loaded poly(lactic-co-glycolic acid)-poly-l-lysine-polyethylene glycol-transferrin (Tf) nanoparticles (DNR-loaded NPs) in hematologic malignancies in vitro and in vivo. Materials and methods DNR-loaded NPs were prepared by the modified double-emulsion solvent evaporation/diffusion method, and its microscopic form was observed under scanning electron microscope. Intracellular distribution of DNR was directly detected by fluorescence microscopy. After establishment of a tumor xenograft model by injecting K562 cells into the left leg of nude mice, the therapeutic effect of the DNR-loaded NPs on the growth of tumors was measured by calculating the tumor size, and the relative expression of Caspase-3 protein was detected by immunohistochemical staining. Furthermore, intracellular concentration of DNR and the extent of cell apoptosis in primary leukemia cells were quantified by flow cytometry. Results DNR-loaded NPs had a spherical shape of about 180 nm in diameter. DNR-loaded NP group showed a significant enhancement of cellular uptake in K562 cells compared with DNR group. Tumor inhibition rate was higher in DNR-loaded NP group in comparison with DNR group, and the relative expression of Caspase-3 protein was upregulated in DNR-loaded NP group compared with DNR group. Furthermore, DNR-loaded NPs obviously increased intracellular concentration of DNR in primary leukemia cells compared with DNR group, but there was no significant difference in primary cell apoptosis between the two groups. These findings suggest that the novel NP DDS can enhance the performance of conventional antitumor drugs and may be suitable for further application in the treatment of hematologic malignancies.
Collapse
Affiliation(s)
- Wen Bao
- Department of Hematology and Oncology, Key Medical Disciplines of Jiangsu Province, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, People's Republic of China,
| | - Ran Liu
- Department of Hematology and Oncology, Key Medical Disciplines of Jiangsu Province, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, People's Republic of China,
| | - Guohua Xia
- Department of Hematology and Oncology, Key Medical Disciplines of Jiangsu Province, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, People's Republic of China,
| | - Fei Wang
- Department of Hematology and Oncology, Key Medical Disciplines of Jiangsu Province, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, People's Republic of China,
| | - Baoan Chen
- Department of Hematology and Oncology, Key Medical Disciplines of Jiangsu Province, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, People's Republic of China,
| |
Collapse
|
37
|
Tripathy D, Hortobagyi G, Chan A, Im SA, Chia S, Yardley D, Esteva FJ, Hurvitz S, Kong O, Bao W, Rodriguez Lorenc K, Diaz-Padilla I, Slamon DJ. Abstract P6-18-05: First-line ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In three separate Phase III randomized, placebo-controlled trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners prolonged progression-free survival (PFS) vs placebo (PBO) + ET in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). Here we further evaluate the efficacy of RIB-based regimens of interest (i.e. with a non-steroidal aromatase inhibitor [NSAI] or fulvestrant [FUL]) in pts who were ET-naïve in the ABC setting, using pooled data from three Phase III trials: MONALEESA (ML)-2 (NCT01958021; all pts), ML-3 (NCT02422615; no prior ET for ABC subgroup only), and ML-7 (NCT02278120; RIB + NSAI subgroup only).
Methods: Postmenopausal pts with no prior ET for ABC received RIB (600 mg/day; 3-weeks-on/1-week-off) or PBO + either letrozole (2.5 mg/day) in ML-2 or FUL (500 mg every 28 days, with an additional dose on Day 15 of Cycle 1) in ML-3. In ML-7, premenopausal pts with no prior ET and ≤1 line of chemotherapy for ABC received RIB or PBO + goserelin (3.6 mg every 28 days) + NSAI (anastrozole [1 mg/day]/letrozole [2.5 mg/day]). The primary endpoint of all three trials was locally assessed PFS. Secondary endpoints included overall response rate (ORR), clinical benefit rate (CBR), and duration of response (DoR; ML-3 and -7). DoR was an exploratory endpoint in ML-2.
Results: Data were pooled for 820 pts treated with RIB + ET (ML-2: n=334; ML-3: n=238; ML-7: n=248) and 710 pts treated with PBO + ET (ML-2: n=334; ML-3: n=129; ML-7: n=247). As of the data cutoffs (ML-2: January 2, 2017; ML-3: November 3, 2017; ML-7: August 20, 2017), in the RIB + ET vs PBO + ET arms, 385 (47%) vs 234 (33%) pts remained on-treatment; the most common reason for discontinuation was disease progression (n=292 [36%] vs n=391 [55%]). In this pooled analysis, median PFS was prolonged for RIB + ET vs PBO + ET, with a hazard ratio of 0.570 (95% confidence interval [CI] 0.491–0.662); median PFS was 25.3 months (95% CI 23.9–29.6) vs 15.6 months (95% CI 14.4–16.9), respectively. Consistent PFS benefit for RIB + ET vs PBO + ET was observed across pt subgroups, including ECOG performance status, age, race, or presence/absence of liver and/or lung metastases or bone-only disease. Among all pts in the pooled analysis, the ORR was 41% for RIB + ET vs 28% for PBO + ET and the CBR was 79% vs 70%, respectively. In pts with measurable disease at baseline (RIB + ET: n=639; PBO + ET: n=542), the ORR was 51% for RIB + ET vs 37% for PBO + ET and the CBR was 79% vs 68%, respectively. In the RIB + ET vs PBO + ET arms, the median DoR was 26.7 months vs 20.0 months. A decrease in best percentage change from baseline in the sum of longest diameters per RECIST was observed in 86% of pts receiving RIB + ET vs 73% of pts receiving PBO + ET.
Conclusions: RIB in combination with various ET partners demonstrates improved clinical outcomes vs PBO + ET across a broad population of pts with HR+, HER2– ABC. These data provide further support for the use of RIB-based combinations in pre- and postmenopausal pts with HR+, HER2– ABC who have received no prior ET for advanced disease.
Citation Format: Tripathy D, Hortobagyi G, Chan A, Im S-A, Chia S, Yardley D, Esteva FJ, Hurvitz S, Kong O, Bao W, Rodriguez Lorenc K, Diaz-Padilla I, Slamon DJ. First-line ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-05.
Collapse
Affiliation(s)
- D Tripathy
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - G Hortobagyi
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - A Chan
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - S-A Im
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - S Chia
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - D Yardley
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - FJ Esteva
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - S Hurvitz
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - O Kong
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - W Bao
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - K Rodriguez Lorenc
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - I Diaz-Padilla
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| | - DJ Slamon
- The University of Texas MD Anderson Cancer Center, Houston; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; NYU Langone Health, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; UCLA Medical Center, Santa Monica
| |
Collapse
|
38
|
Burris HA, Chan A, Im SA, Chia S, Tripathy D, Esteva FJ, Campone M, Bardia A, Kong O, Bao W, Diaz-Padilla I, Rodriguez Lorenc K, Yardley DA. Abstract P6-18-15: Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In Phase III trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners has demonstrated significantly prolonged progression-free survival vs placebo (PBO) + ET in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). Here we further evaluate the safety of RIB-based regimens of interest for the proposed indication (i.e. with a non-steroidal aromatase inhibitor [NSAI] or fulvestrant [FUL]) using pooled data from three Phase III trials (MONALEESA [ML]-2 [NCT01958021], -3 [NCT02422615], and -7 [NCT02278120]).
Methods: Postmenopausal pts with HR+, HER2– ABC received RIB (600 mg/day; 3-weeks-on/1-week-off) or PBO + letrozole (LET; 2.5 mg/day; ML-2 [no prior ET for ABC]) or FUL (500 mg, Days 1 and 15 of Cycle 1, then Day 1 of every cycle thereafter; ML-3; no or ≤1 prior line of ET for ABC]). Premenopausal pts (ML-7; no prior ET and ≤1 chemotherapy for ABC]) received RIB or PBO + anastrozole (1 mg/day)/LET (2.5 mg/day) + goserelin (3.6 mg every 28 days). Adverse events (AEs) were characterized per Common Terminology Criteria for Adverse Events v4.03; safety analyses included time to first event, duration of event, and rate of associated RIB/PBO discontinuations.
Results: Data for 1883 pts were pooled; 1065 pts received RIB + ET and 818 pts received PBO + ET (median exposure to study treatment: 17 and 13 months, respectively). Exposure-adjusted incidence rates for AEs of special interest were 561 and 131 per 100 pt-years in the RIB and PBO arms, respectively. The most common all-causality Grade 3/4 AEs (≥10% in any arm; RIB vs PBO) were neutropenia (59% vs 2%), leukopenia (18% vs 1%), and hypertension (13% vs 13%). A new Fridericia's corrected QT interval (QTcF) >480 ms occurred in (n/N) 52/1054 (5%) vs 11/814 (1%) pts in the RIB vs PBO arms; a new QTcF >500 ms occurred in 14/1054 (1%) vs 1/814 (<1%) pts. Median time to first event for Grade ≥2 neutropenia, elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), and QTc prolongation in the RIB arm was 2, 12, and 2 weeks, respectively; median duration of first Grade ≥2 event was 4, 4, and 2 weeks. In the RIB arm vs PBO arms, 7% vs 3% of pts discontinued study treatment due to AEs; common all-grade AEs leading to RIB/PBO discontinuation (≥2% in any arm) were elevated ALT (4% vs <1%) and elevated AST (2% vs 1%). Discontinuation due to QT prolongation occurred in 4 pts in the RIB arm and 2 in the PBO arm (both <1%). All-grade serious AEs occurred in 25% of pts in the RIB arm vs 15% of pts in the PBO arm.
Conclusions: RIB in combination with various ET partners continues to demonstrate a predictable and manageable tolerability profile across a broad population of pts with HR+, HER2– ABC.
Citation Format: Burris HA, Chan A, Im S-A, Chia S, Tripathy D, Esteva FJ, Campone M, Bardia A, Kong O, Bao W, Diaz-Padilla I, Rodriguez Lorenc K, Yardley DA. Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-15.
Collapse
Affiliation(s)
- HA Burris
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - A Chan
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - S-A Im
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - S Chia
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - D Tripathy
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - FJ Esteva
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - M Campone
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - A Bardia
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - O Kong
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - W Bao
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - I Diaz-Padilla
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - K Rodriguez Lorenc
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - DA Yardley
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| |
Collapse
|
39
|
Wachter R, Michele S, Witte K, Straburzynska-Migaj E, Belohlavek J, Fonseca C, Mueller C, Lonn E, Bao W, Noe A, Schwende H, Butylin D, Pascual-Figal D. In-Hospital Initiation of Sacubitril/Valsartan in Stabilised Patients with Heart Failure and Reduced Ejection Fraction Naïve to Renin-Angiotensin System Blocker: An Analysis of the Transition Study. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Wachter R, Michele S, Witte K, Straburzynska-Migaj E, Belohlavek J, Fonseca C, Mueller C, Lonn E, Bao W, Noe A, Schwende H, Butylin D, Pascual-Figal D. Initiation of Sacubitril/Valsartan in Patients with De Novo Heart Failure with Reduced Ejection Fraction: An Analysis of the Transition Study. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
41
|
Lei LS, Xue CG, Xu XT, Jin DP, Wang SH, Bao W, Liang H, Zhang K, Asiri AM. The synthesis of cyanoformamides via a CsF-promoted decyanation/oxidation cascade of 2-dialkylamino-malononitriles. Org Biomol Chem 2019; 17:3723-3726. [DOI: 10.1039/c9ob00510b] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The synthesis of cyanoformamides via a CsF-promoted decyanation/oxidation cascade of N,N-disubstituted aminomalononitriles.
Collapse
Affiliation(s)
- Lin-Sheng Lei
- School of Pharmacy
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Cao-Gen Xue
- School of Pharmacy
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Xue-Tao Xu
- School of Chemical and Environmental Engineering
- Wuyi University
- Jiangmen 529020
- P. R. China
| | - Da-Ping Jin
- School of Pharmacy
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Shao-Hua Wang
- School of Pharmacy
- Lanzhou University
- Lanzhou 730000
- P. R. China
- School of Chemical and Environmental Engineering
| | - Wen Bao
- School of Pharmacy
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Huan Liang
- School of Pharmacy
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Kun Zhang
- School of Chemical and Environmental Engineering
- Wuyi University
- Jiangmen 529020
- P. R. China
| | - Abdullah M. Asiri
- Chemistry Department
- King Abdulaziz University
- Jeddah 21589
- Saudi Arabia
| |
Collapse
|
42
|
Warren RB, Reich K, Langley RG, Strober B, Gladman D, Deodhar A, Bachhuber T, Bao W, Altemeyer E, Hussain S, Safi J. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol 2018; 179:1205-1207. [PMID: 29927479 DOI: 10.1111/bjd.16901] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- R B Warren
- The Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Biomedical Research Centre, The University of Manchester, Manchester, U.K
| | - K Reich
- Dermatologikum Berlin and SCIDerm Research Institute, Hamburg, Germany
| | - R G Langley
- Dalhousie University, Halifax, NS, B3H, Canada
| | - B Strober
- University of Connecticut Health Center, Farmington, CT, U.S.A.,Probity Medical Research, Waterloo, ON, Canada
| | - D Gladman
- Toronto Western Hospital, Toronto, ON, Canada
| | - A Deodhar
- Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, U.S.A
| | | | - W Bao
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, U.S.A
| | | | - S Hussain
- Novartis Healthcare Pvt Ltd, Hyderabad, India
| | - J Safi
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, U.S.A
| |
Collapse
|
43
|
Zhang B, Li C, Bao W, Li Y, Tian S, Qiu X, Bai Y. Exercise brings balance of glucose metabolism to bilateral motor pathways in cerebral ischemic rat: A preliminary study using micropet. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Yeomans ND, Graham DY, Husni ME, Solomon DH, Stevens T, Vargo J, Wang Q, Wisniewski LM, Wolski KE, Borer JS, Libby P, Lincoff AM, Lüscher TF, Bao W, Walker C, Nissen SE. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther 2018; 47:1453-1463. [PMID: 29667211 DOI: 10.1111/apt.14610] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 12/09/2017] [Accepted: 02/21/2018] [Indexed: 12/18/2022]
Abstract
AIM To evaluate GI safety of celecoxib compared with 2 nonselective (ns) NSAIDs, as a secondary objective of a large trial examining multiorgan safety. METHODS This randomised, double-blind controlled trial analysed 24 081 patients. Osteoarthritis or rheumatoid arthritis patients, needing ongoing NSAID treatment, were randomised to receive celecoxib 100-200 mg b.d., ibuprofen 600-800 mg t.d.s. or naproxen 375-500 mg b.d. plus esomeprazole, and low-dose aspirin or corticosteroids if already prescribed. Clinically significant GI events (CSGIE-bleeding, obstruction, perforation events from stomach downwards or symptomatic ulcers) and iron deficiency anaemia (IDA) were adjudicated blindly. RESULTS Mean treatment and follow-up durations were 20.3 and 34.1 months. While on treatment or 30 days after, CSGIE occurred in 0.34%, 0.74% and 0.66% taking celecoxib, ibuprofen and naproxen. Hazard ratios (HR) were 0.43 (95% CI 0.27-0.68, P = 0.0003) celecoxib vs ibuprofen and 0.51 (0.32-0.81, P = 0.004) vs naproxen. There was also less IDA on celecoxib: HR 0.43 (0.27-0.68, P = 0.0003) vs ibuprofen; 0.40 (0.25-0.62, P < 0.0001) vs naproxen. Even taken with low-dose aspirin, fewer CSGIE occurred on celecoxib than ibuprofen (HR 0.52 [0.29-0.94], P = 0.03), and less IDA vs naproxen (0.42 [0.23-0.77, P = 0.005]). Corticosteroid use increased total GI events and CSGIE. H. pylori serological status had no influence. CONCLUSIONS Arthritis patients taking NSAIDs plus esomeprazole have infrequent clinically significant gastrointestinal events. Co-prescribed with esomeprazole, celecoxib has better overall GI safety than ibuprofen or naproxen at these doses, despite treatment with low-dose aspirin or corticosteroids.
Collapse
Affiliation(s)
- N D Yeomans
- Department of Medicine, Austin Hospital, University of Melbourne, Melbourne, Victoria, Australia
- Western Sydney University, Campbelltown, NSW, Australia
| | - D Y Graham
- Baylor College of Medicine, Veterans Affairs Medical Center, Houston, TX, USA
| | - M E Husni
- Cleveland Clinic, Cleveland, OH, USA
| | - D H Solomon
- Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA
| | - T Stevens
- Cleveland Clinic, Cleveland, OH, USA
| | - J Vargo
- Cleveland Clinic, Cleveland, OH, USA
| | - Q Wang
- Cleveland Clinic, Cleveland, OH, USA
| | | | | | - J S Borer
- Downstate College of Medicine, State University of New York, New York, NY, USA
| | - P Libby
- Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA
| | | | - T F Lüscher
- Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
| | - W Bao
- Pfizer, New York, NY, USA
| | | | | | | |
Collapse
|
45
|
Zhan P, Dukik K, Li D, Sun J, Stielow JB, Gerrits van den Ende B, Brankovics B, Menken SBJ, Mei H, Bao W, Lv G, Liu W, de Hoog GS. Phylogeny of dermatophytes with genomic character evaluation of clinically distinct Trichophyton rubrum and T. violaceum. Stud Mycol 2018; 89:153-175. [PMID: 29910521 PMCID: PMC6002342 DOI: 10.1016/j.simyco.2018.02.004] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Trichophyton rubrum and T. violaceum are prevalent agents of human dermatophyte infections, the former being found on glabrous skin and nail, while the latter is confined to the scalp. The two species are phenotypically different but are highly similar phylogenetically. The taxonomy of dermatophytes is currently being reconsidered on the basis of molecular phylogeny. Molecular species definitions do not always coincide with existing concepts which are guided by ecological and clinical principles. In this article, we aim to bring phylogenetic and ecological data together in an attempt to develop new species concepts for anthropophilic dermatophytes. Focus is on the T. rubrum complex with analysis of rDNA ITS supplemented with LSU, TUB2, TEF3 and ribosomal protein L10 gene sequences. In order to explore genomic differences between T. rubrum and T. violaceum, one representative for both species was whole genome sequenced. Draft sequences were compared with currently available dermatophyte genomes. Potential virulence factors of adhesins and secreted proteases were predicted and compared phylogenetically. General phylogeny showed clear gaps between geophilic species of Arthroderma, but multilocus distances between species were often very small in the derived anthropophilic and zoophilic genus Trichophyton. Significant genome conservation between T. rubrum and T. violaceum was observed, with a high similarity at the nucleic acid level of 99.38 % identity. Trichophyton violaceum contains more paralogs than T. rubrum. About 30 adhesion genes were predicted among dermatophytes. Seventeen adhesins were common between T. rubrum and T. violaceum, while four were specific for the former and eight for the latter. Phylogenetic analysis of secreted proteases reveals considerable expansion and conservation among the analyzed species. Multilocus phylogeny and genome comparison of T. rubrum and T. violaceum underlined their close affinity. The possibility that they represent a single species exhibiting different phenotypes due to different localizations on the human body is discussed.
Collapse
Affiliation(s)
- P Zhan
- Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China.,Dermatology Hospital of Jiangxi Provinces, Jiangxi Dermatology Institute, Nanchang, China.,Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.,Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands
| | - K Dukik
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.,Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands
| | - D Li
- Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China.,Georgetown University Medical Center, Department of Microbiology and Immunology, Washington, DC, USA
| | - J Sun
- Guangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China
| | - J B Stielow
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.,Thermo Fisher Scientific, Landsmeer, The Netherlands.,Center of Expertise in Mycology of Radboudumc/Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
| | | | - B Brankovics
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.,Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands
| | - S B J Menken
- Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands
| | - H Mei
- Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China
| | - W Bao
- Nanjing General Hospital of Nanjing Command, Nanjing, China
| | - G Lv
- Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China
| | - W Liu
- Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China
| | - G S de Hoog
- Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.,Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands.,Thermo Fisher Scientific, Landsmeer, The Netherlands.,Center of Expertise in Mycology of Radboudumc/Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
| |
Collapse
|
46
|
Bao W, Wang JQ, Xu XT, Zhang BH, Liu WT, Lei LS, Liang H, Zhang K, Wang SH. Copper-catalyzed cyclization of 2-cyanobenzaldehydes and 2-isocyanoacetates: an efficient strategy for the synthesis of substituted 1-aminoisoquinolines. Chem Commun (Camb) 2018; 54:8194-8197. [DOI: 10.1039/c8cc04733b] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
An efficient strategy for the synthesis of substituted 1-aminoisoquinoline has been developed.
Collapse
Affiliation(s)
- Wen Bao
- School of Pharmacy
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Jun-Qi Wang
- School of Pharmacy
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Xue-Tao Xu
- School of Chemical and Environmental Engineering
- Wuyi University
- Jiangmen 529020
- P. R. China
| | - Bang-Hong Zhang
- School of Pharmacy
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Wei-Ting Liu
- School of Pharmacy
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Lin-Sheng Lei
- School of Pharmacy
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Huan Liang
- School of Pharmacy
- Lanzhou University
- Lanzhou 730000
- P. R. China
| | - Kun Zhang
- School of Chemical and Environmental Engineering
- Wuyi University
- Jiangmen 529020
- P. R. China
| | - Shao-Hua Wang
- School of Pharmacy
- Lanzhou University
- Lanzhou 730000
- P. R. China
- School of Chemical and Environmental Engineering
| |
Collapse
|
47
|
Shao H, Bao W, Jing ZR, Wang YP, Zhang FM, Wang SH, Tu YQ. Construction of the [6,5,7,5] Tetracyclic Core of Calyciphylline A Type Alkaloids via a Tandem Semipinacol Rearrangement/Nicholas Reaction. Org Lett 2017; 19:4648-4651. [PMID: 28836793 DOI: 10.1021/acs.orglett.7b02274] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A novel and efficient approach toward the assembly of the synthetically challenging tetracyclic [6,5,7,5] core structure of calyciphylline A-type alkaloids is developed. The synthetic route features a tandem semipinacol rearrangement/Nicholas reaction that has been devised strategically to construct the spirocyclic A/B ring and the sterically congested vicinal all-carbon quaternary carbon centers in high diastereoselectivity. Late-stage installation of the hydropyrrole ring and the strained 7-membered ring via a double-reductive amination and ring-closing metathesis, respectively, has also been realized.
Collapse
Affiliation(s)
- Hui Shao
- School of Chemistry & Chemical Engineering, Shanghai Jiao Tong University , Shanghai 200240, P. R. China
| | - Wen Bao
- State Key Laboratory of Applied Organic Chemistry & School of Pharmacy, Lanzhou University , Lanzhou 730000, P. R. China
| | - Ze-Ran Jing
- State Key Laboratory of Applied Organic Chemistry & School of Pharmacy, Lanzhou University , Lanzhou 730000, P. R. China
| | - Yun-Peng Wang
- State Key Laboratory of Applied Organic Chemistry & School of Pharmacy, Lanzhou University , Lanzhou 730000, P. R. China
| | - Fu-Min Zhang
- State Key Laboratory of Applied Organic Chemistry & School of Pharmacy, Lanzhou University , Lanzhou 730000, P. R. China
| | - Shao-Hua Wang
- State Key Laboratory of Applied Organic Chemistry & School of Pharmacy, Lanzhou University , Lanzhou 730000, P. R. China
| | - Yong-Qiang Tu
- School of Chemistry & Chemical Engineering, Shanghai Jiao Tong University , Shanghai 200240, P. R. China.,State Key Laboratory of Applied Organic Chemistry & School of Pharmacy, Lanzhou University , Lanzhou 730000, P. R. China
| |
Collapse
|
48
|
Ding Z, Qiu J, Shen Y, Chen Z, Bao W. Lens-free all-fiber probe with an optimized output beam for optical coherence tomography. Opt Lett 2017; 42:2814-2817. [PMID: 28708176 DOI: 10.1364/ol.42.002814] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Accepted: 06/19/2017] [Indexed: 06/07/2023]
Abstract
A high-efficiency lensless all-fiber probe for optical coherence tomography (OCT) is presented. The probe is composed of a segment of large-core multimode fiber (MMF), a segment of tapered MMF, and a length of single-mode fiber (SMF). A controllable output beam can be designed by a simple adjustment of its probe structure parameters (PSPs), instead of the selection of fibers with different optical parameters. A side-view probe with a diameter of 340 μm and a rigid length of 6.37 mm was fabricated, which provides an effective imaging range of ∼0.6 mm with a full width at half-maximum beam diameter of less than 30 μm. The insertion loss of the probe was measured to be 0.81 dB, ensuring a high sensitivity of 102.25 dB. Satisfactory images were obtained by the probe-based OCT system, demonstrating the feasibility of the probe for endoscopic OCT applications.
Collapse
|
49
|
Liu Y, Bao W. AWARENESS OF ALZHEIMER’S DISEASE AMONG NURSES WORKING IN GENERAL HOSPITAL IN BEIJING, CHINA. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.3315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Y. Liu
- School of Nursing,Peking University, Beijing, China,
| | - W. Bao
- Beijing Hospital, Beijing, China
| |
Collapse
|
50
|
Bao W, Ding Z, Qiu J, Shen Y, Li P, Chen Z. Quasi-needle-like focus synthesized by optical coherence tomography. Opt Lett 2017; 42:1385-1388. [PMID: 28362775 DOI: 10.1364/ol.42.001385] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
It is known that lateral resolution and depth of focus (DOF) in an optical imaging system are coupled, and a compromise between them has to be made. In this Letter, we propose to resolve the trade-off between lateral resolution and the DOF by a synthetic effective point spread function in optical path length (OPL) domain. A quasi-needle-like focus is synthesized by optical coherence tomography. We demonstrate that the synthesized quasi-needle-like focus provides a four-fold extension of a conventional DOF, while maintaining a high lateral resolution of 2.5 μm over a depth range of approximately 240 μm. The focal range can be further extended with more optical path length coded beams for synthesis involved.
Collapse
|